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Background: Oral HPV infection is etiologically associated with a subset of Head and Neck 
Squamous Cell Carcinomas (HNSCCs).  However, the natural history and risk factors of this 
infection are largely unexplored particularly in high risk groups such as HIV-infected 
individuals.  
Objectives: This dissertation aims to examine the natural history and risk factors for oral 
HPV infection and HPV-related HNSCC in HIV-infected and HIV-uninfected individuals. 
Methods: We utilized three different longitudinal studies involving HIV-infected individuals. 
We semi-annually collected oral rinse samples (in the first and second studies) and anal 
swabs (in the first study) and analyzed them for 37 different HPV DNA types utilizing the 
Roche Linear array.  In the third study, HNSCCs were validated through chart review or 
through cancer registry-linkage. In each study, we collected information on biologic and 
behavior risk factors. We analyzed data utilizing 1) Kaplan-Meier survival analysis, 2) Wei-
Lin-Weissfeld regression, and 3) Mixed effects Poisson regression. 
Results: Study 1: Among HIV-infected individuals, the prevalence (84% vs. 28%), incidence 
(aHR=4.7, 95%CI=3.6-6.2) and persistence (aHR=1.5, 95%CI=1.2-1.9) were all significantly 
higher for anal versus oral HPV infections, respectively.   
Study 2: While 28% of HIV-infected and at risk HIV-uninfected participants had at least one 
type-specific incident oral HPV infection within 24 months, only 7% of incident oral HPV 
infections were persistently detected for two or more years. Oral sex and 
immunosuppression were associated with increased risk of oral HPV infection, while male 
gender, older age, and current cigarette smoking were associated with increased persistence.   
Study 3: HPV-related HNSCC is three times more common in HIV-infected individuals 
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compared to the general population. HNSCC was associated with reduced CD4 measured 
prior to cancer diagnosis.  
Conclusion: Oral HPV infection is regularly detected in HIV-infected individuals, but 
commonly clears and HPV-related HNSCC is only modestly elevated in HIV-infected 
individuals compared to the general population. Older age, gender/sexual orientation, 
cigarette smoking, and oral sexual behaviors all appear to impact the natural history of oral 
HPV. HIV-related immunosuppression appears to have the strongest impact in the 
acquisition or re-activation of oral HPV, but may have a modest role throughout the oral 
carcinogenesis process.  
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Note:   
The following chapter is modified from a paper published in the “Current Opinions 
in Oncology” in September 2013 (Beachler et al, 2013 Sept, 25(5):503-11). 
 
Introduction: 
Human Papillomavirus (HPV) infection, a commonly detected DNA virus widely 
known as the necessary cause of cervical cancer,1 has been established as a major etiologic 
factor for head and neck squamous cell carcinoma (HNSCC).2 Research suggests that HIV-
infected individuals are at higher risk for oral HPV infection and HPV-associated HNSCC.3,4  
In this introductory chapter, we review the literature on the risk factors and burden of oral 
HPV and HPV-associated HNSCC among HIV-infected individuals, discuss cancer 
prevention possibilities, and suggest future research directions. 
HPV and Head and Neck Squamous Cell Carcinoma Overview: 
HNSCC is a heterogeneous group of cancers that includes cancer of the oral cavity 
pharynx, and larynx, and is the one of the ten most common cancers worldwide with an 
annual incidence of over 300,000.5 HPV is known to cause a subset of HNSCCs, with HPV-
associated HNSCCs having distinct genetic, clinical, and epidemiological characteristics from 
HPV-unassociated HNSCCs.6 HPV-associated HNSCCs represent approximately 25% of all 
HNSCCs in the general population,7,8 and usually arise in the oropharynx, which includes the 
base of the tongue and the lingual and palatine tonsils.9 These cancers are independently 
associated with sexual behavior including recent and lifetime number of oral sex partners.6 In 
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contrast, the majority of HPV-unassociated HNSCCs occur in the oral cavity and larynx and 
are primarily associated with tobacco and alcohol use.6  
Control of the cell cycle is impacted in both HPV-associated and HPV-unassociated 
cancers. HPV-associated HNSCCs involve E6 and E7 oncogene expression, which 
functionally inactivate tumor suppressor genes p53 and pRB, while HPV-unassociated 
HNSCCs mutationally inactivate p53 and p16, which can lead to unregulated cell growth.10,11  
HPV-associated HNSCCs, which now account for many of the HNSCCs diagnosed before 
age 60, have shown better response to chemotherapy and radiotherapy, and improved 
survival compared to HPV-unassociated HNSCCs. 12,13 
The incidence of HPV-associated HNSCC has increased in the general population of 
many developed countries over the past several decades.14,15 This increase could be explained 
by generational differences in sexual behavior or increased persistence or progression of oral 
HPV due to changes in co-factors. Despite this increasing trend of HPV-associated HNSCC, 
the natural history of oral HPV has been largely unexplored. 
Oral HPV infection among HIV-infected individuals: 
While the natural history of oral HPV has been largely uninvestigated, several cross-
sectional studies have observed that HIV-infected individuals have a 2-3 fold higher odds of 
prevalent oral HPV infection compared to HIV-uninfected individuals, even after 
adjustment for sexual behavior and other relevant factors.3,16 Recent studies suggest HIV-
infected individuals have an overall oral HPV DNA prevalence between 20% and 45% (in 
the alpha genus), and an oncogenic oral HPV DNA prevalence between 12% and 26%, 
(Table 1.1).3,16,17 HPV16, which causes more than 80% of HPV-associated oropharyngeal 
cancers,7,18 is the most commonly detected oral HPV type in HIV-infected individuals with a 
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prevalence around 2-6%.16,19-21 In contrast, a study utilizing a representative population of the 
United States (US) found that 7% of healthy adults have a detectable oral HPV infection, 
while about 1% have detectable oral HPV16.22  Estimates of oral HPV prevalence among 
HIV-infected individuals likely vary because of multiple factors including differences in 
sample collection, processing, number of HPV types tested, DNA detection methods, and 
the study participant characteristics (Table 1.1).  While oral HPV prevalence is considerably 
lower than prevalence of anogenital HPV infection in HIV-infected and HIV-uninfected 
individuals,23 it is unclear if this is due to reduced incidence or persistence of oral as 
compared to anogenital HPV infection.  
Head and neck squamous cell carcinoma in HIV-infected individuals: 
The risks of several different cancer types are elevated in HIV-infected individuals 
due to behavioral and biological characteristics, immunodeficiency, and potentially chronic 
inflammation and immune dysfunction/senescence.24 Indeed, HIV-infected individuals in 
developed countries have a modestly increased risk of both HPV-associated and HPV-
unassociated HNSCCs compared to the general population. AIDS-cancer registry match 
studies have found that the standardized incidence ratios (SIRs) for HNSCC are between 1.5 
and 4 fold higher among HIV-infected individuals compared with the general population 
(Table 1.2).4,25-29  
HIV-infected individuals are also at increased risk of laryngeal, oral cavity and other 
HPV-unassociated HNSCCs,4 which is likely due to their high prevalence of tobacco use,30 
the strongest risk factor for these cancers.31 While these registry match studies are not 
typically adjusted for potential confounders other than age, one recent study that did control 
for risk factors including tobacco and alcohol use found a non-significant overall increased 
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risk of oral cavity/pharynx cancer for HIV-infected as compared to HIV-uninfected 
individuals in California (aRR=1.4, 95%CI=0.9-2.1).29   
  While most studies have considered all HNSCC sites together, several registry-match 
studies attempted to quantify the risk of HPV-associated HNSCC by exploring cancer risk in 
specific anatomical subsites. These studies reported a 1.5-4 fold higher risk of oropharyngeal 
or tonsillar cancer for HIV-infected individuals compared to the general population (Table 
1.2).4,25,28,32 While estimates suggest that half or more of oropharyngeal cancers are HPV-
positive in the general population,14,15 the proportion of HPV-positive oropharyngeal tumors 
in HIV-infected individuals is unknown. While their exact level of risk is unclear, HIV-
infected individuals appear to be at moderately increased risk of HPV-associated HNSCC 
compared to the general population based on the modestly higher oropharyngeal cancer 
incidence. Interestingly, the magnitude of this increase (SIR~1.5-4) is lower than other HPV-
associated cancers such as anal, cervical, vulvar, and penile cancer which each have SIRs of 5 
or greater.4,28  
Impact of Sexual Behavior: 
An increased number of oral sexual partners is a risk factor for both oral HPV 
infection16,33 and HPV-associated HNSCC.6 Given the high number of lifetime sexual 
partners among many HIV-infected individuals,16,34 one might expect the incidence of HPV-
associated HNSCC among HIV-infected individuals to be higher than what is currently 
observed; particularly among the most sexual active groups such as men who have sex with 
men (MSM).16,35 However, several registry based studies have found a non-significantly lower 
incidence of oropharyngeal cancer in HIV-infected MSM compared to HIV-infected 
injection drug users and heterosexual men (Table 1.2).25,26,28 One potential explanation is that 
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the probability of acquiring oral HPV from performing oral sex on a man (fellatio) may be 
lower than when performing oral sex on a woman (cunnilingus). While studies have not 
extensively compared HIV-uninfected MSM and men, two large studies recently suggested 
that oral HPV DNA prevalence22 and HPV-associated oropharyngeal cancer14 are 
considerable higher in males compared to females in the US general population.  
There are at least two hypotheses as to why oral HPV may be more transmissible 
when performing oral sex on women. One hypothesis is that the female genital region may 
have a greater HPV viral load than the male genitals,36-39 despite similarities in genital HPV 
DNA prevalences,40-42 and that this higher viral load could increase the likelihood of oral 
HPV acquisition. In contrast, a second hypothesis suggests that the keratinized epithelium 
from male genitals may be less likely to induce an immune (antibody) response than mucosal 
surfaces such as the cervix or the anal canal.43,44 Thus, the high level of natural antibodies 
developed after a cervical or anal HPV infection in women and MSM might conceivably be 
more likely to protect them from acquiring subsequent oral HPV infections.43,45-47 Further 
investigation is necessary to explore these hypotheses. 
These hypotheses coupled with the demographics of the HIV-epidemic in developed 
countries may in part explain the moderate risk of HPV-associated HNSCC seen in the 
HIV-infected population. In the US, approximately half of HIV-infected individuals are 
MSM, while a little over a quarter are women (who are almost all heterosexual).48 This 
suggests that the proportion of heterosexual males (who perform oral sex on women) is 
lower among the HIV-infected population than the general population. If the risk of 
acquiring oral HPV infection is truly highest among heterosexual males, then this could help 
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explain the relatively moderate risk of HPV-associated HNSCC (compared to other HPV-
associated cancers) seen in HIV-infected individuals in developed countries. 
Impact of Immunosuppression and Antiretroviral Therapy (ART) Use: 
HIV-related immunosuppression may be a strong risk factor for oral HPV incidence 
or persistence given the 2-3 times higher adjusted odds of oral HPV prevalence in HIV-
infected individuals compared to HIV-uninfected individuals.3,16 Advanced stage of HIV 
disease, characterized by low CD4 T cell count and high HIV RNA viral load, has also been 
associated with increased oral HPV prevalence which may reflect a loss of viral control in 
those with compromised immune systems (Figure 1.1).3,16 
The direct effect of immunosuppression on oral HPV persistence and HPV-
associated HNSCC is currently less understood, but research on other HPV-associated 
cancers suggest immunosuppression may act more on the earlier stages of the HPV 
carcinogenesis process.25,49 Oral cavity/pharynx cancer is elevated among both HIV-infected 
individuals and solid organ transplant recipients (another immunosuppressed population) 
suggesting a potential link between immunosuppression and HPV-associated HNSCC.50 In 
addition, three studies have found that the incidence of oral cavity/pharynx cancer was 
higher, although not significantly so, among those with a reduced CD4 T cell count.26,29,51 
Engels et al also observed a higher risk of oral cavity/pharynx cancer in individuals with 
AIDS relative to HIV-infected individuals who have not developed AIDS.51 However, 
another recent study suggested reduced CD4 at AIDS diagnosis was associated with a reduced 
risk of oropharyngeal cancer among patients 28-60 months after AIDS offset.28 One 
explanation for the heterogeneity of these results could be that a higher proportion of HPV-
unassociated HNSCCs occur in certain populations, as HPV tumor status has not been 
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explored and HPV-associated and unassociated HNSCC might be differentially related to 
immunosuppression. These registry based studies also lack detailed covariate information 
such as sexual behavior and smoking status and cannot comprehensively evaluate the effect 
of cumulative and recent immunosuppression.  
Effective antiretroviral therapy (ART, also known as HAART) has greatly improved 
the life expectancy of HIV-infected individuals while reducing viral-related malignancies 
such as Kaposi Sarcoma and Non-Hodgkin’s lymphoma.52 However, the incidence rates of 
HPV-associated malignancies have remained stable in the ART era, or have increased in the 
case of anal cancer. A preliminary study suggested ART use was associated with increased six 
month oral HPV persistence,53 and other studies have suggested ART use is associated with 
an increase in oral lesions/warts.54,55 However, these studies may be prone to confounding 
by indication, as ART is more likely to be indicated for sicker individuals.  
The role of ART on cervical HPV and related squamous epithelial lesions (SILs) has 
been more extensively explored with the majority of well-designed studies suggesting a 
benefit.56-58 While some of the initial studies suggested a similar cervical HPV persistence and 
progression of SILs comparing ART users and non-users,59,60 more recent reports suggest 
ART reduces the incidence of cervical HPV,57 decreases the incidence of squamous epithelial 
lesions56,58 and increases the regression of these lesions.56,57 However, if ART use does not 
fully recover oral HPV-specific immunity it may not be able to substantially modify the 
elevated oral HPV incidence or persistence seen in HIV-infected individuals. Therefore, 
HPV-associated HNSCC could pose an increased threat for immune-competent HIV-




Tobacco use and other co-factors for HPV-associated HNSCC: 
Although HPV-associated HNSCC has often been described as a cancer among non-
smokers and non-drinkers, there is growing evidence that tobacco may play a substantial role 
in the development of some of these cancers.61 Tobacco use is an established risk factor for 
cervical cancer,62 and is associated with oral HPV prevalence 22,33,63,64 and six month oral 
HPV persistence23 in HIV-infected and HIV-uninfected individuals. Other studies have 
shown tobacco use can reduce the innate and cell-mediated immunity at the systemic level 
and in the local oral region65,66, suggesting an immunosuppressive effect of tobacco.  
The direct role of tobacco on HPV-associated HNSCCs is less clear as several 
studies have found an association with increased risk,18,67-69 while others have not.6,70 This 
question is particularly important for HIV-infected individuals, as the prevalence of tobacco 
use in this population is considerable higher than the general population with estimates 
suggesting 40-70% of HIV-infected individuals in developed countries may be current 
smokers.30,71 
There are several other factors being investigated that may increase the risk of HPV-
associated HNSCC including marijuana and alcohol use. While there is a lack of data on 
these factors in HIV-infected individuals, epidemiologic studies among HIV-uninfected 
individuals have found inconsistent results between risk of HPV-associated HNSCC and 
both marijuana 6,72-74 and alcohol use 6,67 as some have observed an association with increased 
risk and others have not.  
Future steps and challenges 
10 
 
While prevention of HPV-associated HNSCC is a developing research area, 
screening for HNSCC remains a challenge. A recent study found that feasibility of an oral 
Pap smear equivalent remains poor in HIV-infected individuals, as the limited number of the 
observed cytopathologic abnormalities was not associated with HPV16.75 Fakhry et al 
suggest that this potential screening tool may not be feasible due to anatomic sampling 
limitations and the relatively low incidence of HNSCC.75   
Although prophylactic vaccination is an effective tool to prevent other HPV-
associated cancers, its efficacy in preventing HPV-associated HNSCC among HIV-infected 
individuals has not yet been evaluated. The recently developed HPV vaccines are likely to 
have the potential to protect against HPV-associated HNSCC, considering they include 
prevention of HPV16, which accounts for over 80% of HPV-associated HNSCCs.7,8,18 While 
rigorous efficacy studies have not been performed, initial observational data suggest the 
vaccine may provide protection against prevalent oral HPV16 and HPV18 in young HIV-
uninfected women.76 The quadrivalent vaccine has been shown to be safe and immunogenic 
among HIV-infected individuals,77,78 and is recommend by the American Council on 
Immunization Practices for HIV-infected individuals aged 11-26.79 Efficacy studies for 
anogenital HPV are currently being performed in older HIV-infected individuals.80  
There are still several other unknowns regarding oral HPV infection and HPV-
associated HNSCC among HIV-infected individuals. First, the proportion of HNSCCs 
cancers caused by HPV among HIV-infected individuals is currently unknown and would 
help to understand its etiology and identify who is at the greatest risk for this disease. In 
addition, the natural history of oral HPV is unstudied, and the incidence and persistence 
rates or oral HPV infection is undefined in both HIV-infected and HIV-uninfected 
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individuals.  It is not clear what factors increase the risk of oral HPV incidence, persistence 
and progression to subsequent HNSCC. The relative effects of HIV, reduced immunity, 
tobacco use, sexual behavior and other factors on the natural history of oral HPV are still 
not well understood. Long term longitudinal studies are needed to further explore these 
factors and how they differ between HIV-infected and HIV-uninfected individuals. 
Conclusion: 
HIV-infected individuals are living longer and therefore may have the opportunity to 
acquire more slowly developing HPV-associated malignancies. Indeed, HIV-infected 
individuals currently appear to have a moderately increased risk of HPV-associated HNSCC, 
which might potentially increase as this population ages. In addition, HIV-infected 
individuals have many of the potential risk factors for this disease (immunosuppression, 
increased sexual partners, tobacco use) and thus should be further studied and considered 
for future potential preventative measures.   
Studies involved in the dissertation: 
Data from several prospective cohort studies involving HIV-infected individuals is 
utilized in this dissertation (Table 1.3). Chapter 2 uses the Human Oral Papillomavirus 
Etiology (HOPE) Study conducted at the Johns Hopkins Hospital’s Moore Clinic in 
Baltimore, Maryland. For this study, 404 HIV-infected participants volunteered oral and anal 
specimens for HPV detection semi-annually between 2006 and 2010. Serum, demographic 
and risk factor information were also collected from this population at baseline.   
Chapter 3 utilizes data from the Persistent Oral human Papillomavirus Study which 
includes 1,230 men from Multicenter AIDS Cohort Study (MACS) and women from 
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Women’s Interagency HIV Study (WIHS).81,82  Both the MACS and WIHS include semi-
annual follow-up of HIV-infected and at risk HIV-uninfected individuals and these studies 
are especially known for the strong retention rates. 
In chapter 4, data from the North American AIDS Cohort Collaboration on 
Research and Design (NA-ACCORD) was utlizied.83 Our study within the NA-ACCORD 
includes individuals from 17 interval and clinical studies, and is one the first to explore Head 
and Neck Squamous Cell Carcinoma (HNSCC) in HIV-infected individuals. The analysis 
involved 82,375 HIV-infected individuals and included 248 cases of HNSCC. 
Specific Aims: 
The specific aims of this dissertation are as follows: 
Aim 1 – Compare the natural histories of oral HPV and anal HPV infection among HIV-
infected women, heterosexual men, and men-who have sex with men 
Hypotheses: 1. Incidence of anal HPV infection is higher than oral HPV, but the persistence of both 
infections is similar 
2. After adjusting for the number of sexual partners, heterosexual men have a higher risk of incident oral 
HPV but a lower risk of incident anal HPV compared to women and men-who have sex with men. 
Aim 2a– Evaluate the effect of HIV and related immunosuppression on newly detected and 
persistent oral HPV infection in the Multicenter AIDS Cohort Study (MACS) and Women’s 
Interagency HIV Study (WIHS). 
Hypothesis: Reduced current CD4 T cell count and reduced nadir CD4 are independently associated with 
persistent oral HPV infection. 
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Aim 2b – Evaluate the effect of other risk factors on newly detected and persistent oral HPV 
infection in the MACS and WIHS 
Hypothesis: Current tobacco use increases the susceptibility of acquiring oral HPV infection when exposed 
and reduces the ability to clear or control oral HPV infections. HIV-infection modifies these relationships. 
Aim 3 –Examine the incidence, calendar trends and risk factors (particularly immune status) 
for HNSCC in a large consortium of HIV-infected individuals in North America (NA-
ACCORD). 
Hypotheses: 1. The incidence of HPV-related HNSCC is elevated in HIV-infected compared to HIV-
uninfected individuals and has been increasing over the past decade among HIV-infected individuals  
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Figure 1.1: Impact of immunosuppression on oral HPV prevalence 
 
aData from a representative sample of the US population, from the National Health and Nutrition Examination 
Survey (NHANES)22 
bData from the Multicenter AIDS Cohort Study (MACS) and Women’s Interagency HIV Study (WIHS),16 
HIV-uninfected individuals in this study were are at-risk for oral HPV due to their higher number of sexual 























Table 1.1: Summary of results from studies reporting prevalence of oral HPV 
DNA among HIV-infected adults, contrasted with US general population 
results 















US men and 
women 
201 oral brush 14% 12% 3.0% 0.5% 
Kreimer et al JID 
20043 






25% 14% --- 5.8% 
Cameron STD 
200517 
US men and 
women 
98 Saliva 37% 26% 6.1% 7.0% 









30 oral brush 20% 7% 0.0% 6.7% 
Fakhry Plos One 
2010~86 
US men and 
women 
112 oral rinse 45% 26% 5.9% --- 
Parisi BMCID 
201187 Italian MSM 166 oral swab 20% 1.5% 0.8% --- 
Beachler et al 
CEBP 201216 
US MSM and 
women 
379 oral rinse 40% 21% 6.1% 19% 







19% 8% 4.4% 7.2% 




100 Saliva 37% 13% 3.0% 6.0% 
Steinau et al 
JOPM 201289 
US men and 
women 
100 oral rinse 39% 24% 3.0% 17% 
Fatahzadeh et al 
OOOOE 2013 90  
US men and 
women 
52 oral rinse 38% 23% 6.0% --- 
Videla et al STD 
201321 Spanish men 650 
oral 
brush/rinse 
16% 15% 5.2% 3.8% 
Beachler et al JID 
2013 
US men and 
women 




2764 ----- 26%^ 15%^ 4.2%^ 8.5%^ 
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5501 oral rinse 7% 3.7% 1.0% --- 
*Number of total alpha HPV types tested varied from 9 (Coutlee 1997) to 47 (Parisi 2011) although 
untyped genotypes were included in the prevalence estimates for several studies (Coutlee 1997, 
Cameron 2005, Del Mistro 2012). Cutaneous HPV types were not included in this summary.  
&Number of oncogenic types varied from 7 (Coutlee 1997) to 22 (Kreimer 2004, Marais 2008) while 
most considered 13-14 types to be oncogenic 
~Average point prevalences reported 
^Pooled oral HPV prevalence summary includes studies with differences in sample collection, 
processing, number of HPV types tested, DNA detection methods, and the study participant 
characteristics 
+Data from a representative sample of the US population, from the National Health and Nutrition 





Table 1.2: Increased risk of head and neck squamous cell carcinoma comparing 
HIV-infected individuals with the general population 
Study Study Population Type of Cancer 












Head and Neck 2.0 (1.1-3.6) --- 




Oral Cavity and 
Pharynx 






Oral Cavity and 
Pharynx 
aRR*=1.4 (0.9-2.1) --- 













Oropharyngeal 1.6 (1.2-2.1) 
MSM: 1.1 (0.7-1.8), 
IDU: 2.1 (1.3-3.2), 
Hetero:3.2 (1.6-5.7) 




Lip, Oral Cavity 
and Pharynx 
4.1 (2.1-7.4) 
MSM: 2.0 (0.4-5.8), 
IDU: 13.7 (4.9-30.1), 
Hetero: 2.9 (0.3-
10.5) 





Tonsillar 2.6 (1.8-3.8) 
Hetero Men: 5.3 
(1.1-15.4) 
&Meta-analysis included three studies considering oropharynx cancers and four studies exploring head and neck 
cancer. 
^Both studies used data from the US HIV/AIDS Cancer match study 
*Relative Risk based on an observational study controlling for potential risk factors such as tobacco and 
alcohol use 




Table 1.3 - Description of studies included in dissertation analyses 





Persistent human Oral 
Papillomavirus Study (POPS) 
North American AIDS 
Cohort Collaboration on 
Research and Design (NA-
ACCORD) 
Description Prospective cohort study 
Prospective study utilizing the 
MACS and WIHS cohorts 
17 Clinical and Interval 
Based studies 
Sample Size 404 1,230 82,375 
Years Studied 2006-2009 2009-2013 1996-2010 
Locations Baltimore, MD 
Baltimore, MD; Washington, 
DC; Chicago, IL; Bronx, NY; 
Brooklyn, NY; Pittsburgh, PA 
Various sites in United 
States and Canada 
Risk Groups 
HIV-infected Men who 
have sex with men (MSM), 
Women, and Heterosexual 
Males 
HIV-infected and HIV-
uninfected Men who have sex 
with men (MSM) and women 








Chapter 2: Natural history of anal versus oral HPV 
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Background: HIV-infected individuals are at greater risk for HPV-associated anal than 
oropharyngeal cancers. The prevalence of anal versus oral HPV infections is higher in this 
population, but whether this is explained by higher incidence or persistence is unknown.  
Methods:  Oral rinse and anal swab samples were collected semi-annually from 404 HIV-
infected adults in Baltimore, MD.  Samples were tested for 37 HPV types using 
PGMY09/11 primers and reverse line-blot hybridization. Risk factors for HPV persistence 
were explored using adjusted Wei-Lin-Weissfeld models. 
Results: The prevalence (84% vs. 28%), incidence (145 vs. 31 per 1000 person-months) and 
twelve-month persistence (54% vs. 29%) were higher for anal versus oral HPV infections, 
respectively (each p<0.001).  Heterosexual men had lower incidence of anal HPV than men-
who-have-sex-with-men and women, but a higher incidence of oral HPV infection (p-
interaction<0.001). In adjusted analyses, risk factors for HPV persistence included prevalent 
versus incident (aHR=4.0, 95%CI=3.5-4.8) and anal versus oral HPV infections (aHR=1.5, 
95%CI=1.2-1.9).   
Conclusion: The higher incidence and persistence of anal versus oral HPV infections likely 
contributes to the higher burden of anal as compared to oral HPV-associated cancers in 





HIV-infected individuals are at elevated risk for all HPV-associated cancers, 
including cervical, anal and oropharyngeal cancers.1-3 However, the standardized incidence 
ratios for these cancers among HIV-infected individuals compared to the general population 
varies considerably by anatomic site. For example, HIV-infected individuals have over a 25-
fold greater risk of anal cancer relative to the general population, but the risk for 
oropharyngeal cancer is only 2-6 fold greater.4,5                        
The underlying reasons for the different magnitudes of risk for HPV-associated 
cancers among HIV-infected individuals are unclear. In the case of cervical cancer, the 
elevated risk among immunosuppressed populations has been attributed to both higher 
incidence6,7 and higher persistence rates6 of cervical HPV infection. Immunosuppression 
may also increase risk of disease progression.8,9 Cross sectional studies have consistently 
shown the prevalence of anal HPV to exceed that of oral HPV among HIV-infected 
individuals.10-12 To investigate the possible contribution of differences in incidence and 
persistence rates to the differing anal-oral HPV prevalence and cancer rates in HIV-infected 
individuals, a prospective study was performed to compare the natural histories of anal and 
oral HPV infections among HIV-infected individuals.  
 
METHODS 
Study Population and Data Collection 
A convenience sample of 404 HIV-infected men and women was recruited from a 
clinic (the Moore clinic) dedicated to the care of HIV-infected individuals at the Johns 
34 
 
Hopkins Hospital (JHH) in Baltimore, MD in 2006. The study was approved by the 
Institutional Review Board at JHH, and written informed consent was collected from all 
participants.  
   Participants were followed semi-annually for up to two and a half years. Baseline 
demographic and behavioral information was collected by use of an audio computer assisted 
self-interview (ACASI) that obtained information regarding demographics, sexual history 
and drug use. Measurement of current CD4 T cell count (Beckton Dickenson BD TriTest) 
and HIV RNA viral load (Roche AMPLICORTM HIV-1 Monitor Test, version 1.5) at 
baseline was performed unless available in the medical record from within six weeks of that 
study visit. Nadir CD4 T cell count and current antiretroviral therapy (referred to hereafter 
as ART, also known as HAART or effective ART) were abstracted from the medical record. 
ART was defined as the use of three or more antiretroviral medications, which includes a 
protease inhibitor (PI), a non-nucleoside reverse transcriptase inhibitor (NNRTI) and one of 
the NRTIs abacavir or tenofovir, an integrase inhibitor, or an entry inhibitor.13    
Specimen Collection, Processing and DNA Purification 
At each visit, exfoliated oral epithelial cells were collected by use of an oral rinse and 
gargle with 10mL of ScopeTM mouthwash.14  A physician collected anal samples by use of a 
saline-moistened Dacron swab inserted six cm into the anal canal and removed in a circular 
motion against the anal wall. The swab was placed in 1 mL of Sample Transport Medium 
(Digene Diagnostics, Silver Spring, MD).11          
Strict procedures were used to prevent specimen contamination as described in 
Koshiol et al.15, including placement of one negative control per seven experimental samples 
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in the PCR plate. DNA was isolated from anal swab and oral rinse samples by 
centrifugation, re-suspension in phosphate buffered saline and purification by use of a 
modified method for the Puregene DNA purification kit (Gentra Systems, Minneapolis, 
MN). Purified DNA was evaluated for the presence of 37 HPV types by use of PGYM09/11 
PCR primer pools and reverse line blot hybridization (Roche Molecular Systems).14,16 
Samples that were β-globin and HPV-negative were considered inevaluable. Line blots were 
independently interpreted by two technicians and discrepancies resolved by the principal 
investigator (MLG).  
Statistical Analyses 
Associations between baseline characteristics and HPV infection (or number of 
visits) were evaluated using chi-squared (χ²) tests for categorical data and t-tests for 
continuous variables. Baseline and follow-up HPV DNA prevalence and 95% confidence 
intervals (CIs) were calculated for HPV16, overall HPV (all 37 types), any oncogenic (16, 18, 
31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68 and 73) and any non-oncogenic (6, 11, 26, 40, 42, 53, 
54, 55, 61, 62, 64, 66, 67, 69, 70, 71, 72, 81, 82, 83, 84, 89 and IS39) type.17-19 HPV infection 
status was evaluated both by person and by type-specific infection. In analyses by individual, 
a participant was considered infected if one or more of the 37 evaluated HPV types were 
detected at each visit. In analyses by infection, presence of each of the 37 type-specific HPV 
infections was evaluated for each individual at each visit (point prevalence). Type-specific 
HPV infections were categorized as prevalent if positive at baseline and incident if first 
detected thereafter. A type-specific infection was only considered to be incident once, even if 
variably detected throughout the study (for example: -+-+). Incidence rates were 
summarized as the number of type-specific infections in the population per 1000 person-
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months. Newly detected anal and oral HPV infections were compared with Hazard Ratios 
(HRs) calculated using the Wei-Lin-Weissfeld (WLW) method,7,20 which is a marginal model 
that consists of a Cox proportional hazard model with an exchangeable correlation structure 
and robust variance to adjust for the correlation between multiple HPV infections detected 
within a single person.7,21   
For prevalent and incident infections, the proportion of infections that persisted to 
6, 12, 18 and 24 months (since infection) were summarized and compared for anal and oral 
HPV infections using prevalence ratios (PRs) from log-binomial regression with Generalized 
Estimating Equations (GEE). Two definitions of type-specific HPV clearance were 
considered: type-specific detection followed by a single negative test or followed by two 
consecutive negative tests. All infections defined as persistent required at least two HPV 
positive visits. Re-detected infections that were initially defined as cleared by either definition 
were not included in these analyses.  
The number of lifetime sexual partners was defined for women as the number of 
vaginal partners and for men was defined as the sum of the reported number of vaginal and 
anal sex partners. Men were categorized based on self-reported sexual preference as either 
heterosexual men preferring only sex with women, or as men who have sex with men 
(MSM). All women were grouped together, as only ten women reported their sexual 
preference as lesbian or bi-sexual. Tobacco exposure included use of cigarettes, pipes, cigars, 
chewing tobacco or snuff, and was described as never, former and current use at baseline. 
Hard drug use was defined as ever using heroin, cocaine, or crack. Recent or current 
behaviors were considered as those performed within six months before this study.  
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Risk factors for prevalent HPV at baseline were explored using log-binomial 
regression with GEE. Unadjusted and adjusted prevalence ratios (PRs and aPRs) and their 
95% confidence intervals (CIs) were reported. Risk factors significantly associated with anal 
or oral prevalence (p<0.05) along with factors shown to be relevant based on previous 
literature were included in the final adjusted models. The combined model considered both 
anal and oral HPV infections as outcomes, and an interaction term with each risk factor and 
the site of infection was evaluated. Trends were evaluated using continuous values for 
ordinal or continuous risk factors, when available.  
Patterns of HPV infection were also described in an analysis restricted to those 
participants with at least two follow-up visits after their first detection of HPV. HPV 
patterns for each infection were defined as persistent (if positive for all the visits following 
the initial positive visit), cleared (if negative for at least the final two visits), or intermittent (if 
varying between positive and negative throughout the visits).  
Time to event outcomes (HPV clearance and persistence) were summarized using 
Kaplan Meier curves, where infections were either considered cleared at the first negative 
visit or only after two consecutive negative visits. The inverses for each association were 
then calculated and reported as HPV persistence. Risk factors for anal and oral HPV 
persistence were explored using the Wei-Lin-Weissfeld (WLW) method. Unadjusted and 
adjusted hazard ratios (HR and aHRs) were reported along with their 95% CIs. For the 
primary persistence analyses, we carried forward the previous visit’s HPV results for missing 
intermittent visits if they were subsequently positive in the next detected visit (example: 
+.+). All statistical tests were two sided and considered significant at an alpha level=0.05. 





The study population was primarily African American (82%) and the median age was 
46 years (Table 2.1). Participants included 153 women (39%), 168 heterosexual men (43%) 
and 69 men-who-have-sex-with-men (MSM-18%). A majority (76%) reported ever 
performing oral sex, while approximately a third (36%) had ever had receptive anal sex. 
Among the 404 individuals enrolled, the median length of follow-up was 18.2 months 
(IQR=6.2, 24.0), with a maximum of 31.6 months. Characteristics of participants who were 
lost to follow-up were similar to those who remained for the full duration of the study (six 
visits). In addition, participants contributing four or more visits were also similar to those 
with three or fewer visits, with the exception of a higher prevalence of ever use of ART 
(p=0.04) among those with four or more visits. 
Anal and Oral HPV prevalence 
A total of 1,137 anal swab samples were collected from the 404 individuals over the 
study period, and 99.1% were evaluable for detection of HPV infection. Prevalent anal HPV 
infections were common at baseline (84%, 95%CI=80%-88%, Table 2.1), as were multiple 
concurrent infections (71%, median 4 [IQR=1-7] HPV types per person). Baseline 
prevalence was highest for anal HPV types 16 (20.3%), 61 (20.0%) and 55 (19.5%). Younger 
age, sexual orientation,  a high number of lifetime anal sex partners and lower current CD4 T 
cell count were associated with prevalent anal HPV infection (each p<0.05, Table 2.2).  
There were 1,292 oral rinse samples collected from the 404 individuals throughout 
the study and 99.1% were evaluable. Prevalent oral HPV infection at baseline was 
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significantly less common than anal HPV infection (28% vs. 84%, p<0.001, Table 2.1), and 
11% of individuals had multiple concurrent oral HPV infections. Baseline prevalence was 
highest for oral HPV types 55 (4.3%), 83 (4.1%), 72 (3.8%). There were no risk factors 
independently associated with prevalent oral HPV infection. After adjustment for risk 
factors such as sexual behavior and current CD4 T cell count, prevalent anal HPV infection 
was 10-fold more common (aPR= 9.8, 95% CI=7.8-12.2) than prevalent oral HPV infection.  
Anal and Oral HPV Incidence 
Given the higher prevalence of anal versus oral HPV infections, we compared 
incidence rates at the two anatomic sites. The incidence of anal infection was significantly 
higher than for oral infection (145 vs. 31 infections per 1000 person-months, aHR=4.7, 
95%CI=3.6-6.2, Table 2.3) particularly among oncogenic types (oncogenic vs. non-
oncogenic, p-interaction=0.01). The anal HPV incidence was higher than oral HPV 
incidence among women (184 vs. 22 per 1000 person-months), MSM (165 vs. 31 per 1000 
person-months) and heterosexual men (96 vs. 38 per 1000 person-months, for all p<0.001). 
Of note, heterosexual men had the highest incidence of oral, but the lowest incidence of anal 
HPV infections (p-interaction<0.001). Poisson regression with GEE was utilized to 
compare the incidence rates of anal and oral HPV infection, and the incidence rate ratios 
between anal and oral HPV were similar to the reported WLW hazard ratios in Table 2.3 
(data not shown). 
We explored baseline factors associated with incident infections at both anatomic 
sites (Table 2.2). Heterosexual males were significantly less likely to have incident anal HPV, 
while significantly more likely to have incident oral HPV (p-interaction<0.001). The 
incidence of anal HPV infection was similar among individuals who did and did not report 
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recent anal sex (161 vs. 140 per 1000 person-months, p-trend=0.54), while the incidence of 
oral HPV was similar among those who did and did not report recent oral sex (36 vs. 27 per 
1000 person months, p-trend=0.15).  
Anal and Oral HPV persistence 
Given the observed higher prevalence and incidence of anal versus oral HPV 
infections, we also compared persistence of infections at the two anatomic sites. When first 
considering HPV persistence, we noted that many anal and oral HPV infections had a 
pattern of intermittent detection during the study (for example: +-+).  
To further investigate patterns of infections, we performed an analysis restricted to 
the 1,426 HPV infections among the 207 individuals with at least two follow-up visits 
following their first detection of HPV. Individuals in this analysis had a median follow-up of 
24.0 months (IQR=18.6-24.5). In this analysis, 38% of all anal and oral infections were 
persistent (positive for all the visits following the initial positive visit), 26% were intermittent 
(varied between positive and negative throughout the visits) and 37% were cleared (negative 
for at least two consecutive visits and not positive for any subsequent visits) (Figure 2.1).  
Given these patterns of infection, we considered both a single negative and two 
consecutive negative definitions for clearance. Regardless of the clearance definition, anal 
HPV infections were significantly more likely to persist than oral infections (Table 2.4 and 
Figure 2.2). After six months, 63% of prevalent anal HPV infections persisted while only 
46% of prevalent oral HPV infections persisted when using the single negative definition 
(PR=1.4, 95%CI=1.1-1.7, Table 2.4). Over the course of the entire two and half year study,  
prevalent anal HPV infections were approximately twice as likely to persist as prevalent oral 
HPV infections when clearance was defined by a single negative test (HR=1.9, 95%CI=1.6-
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2.3, p<0.001, Figure 2.2A) or two consecutive negative tests (HR=2.0, 1.5-2.6, p<0.001, 
Figure 2.2C). Incident anal infections had a non-significantly higher persistence rate 
compared to incident oral infections using the single negative test definition (HR=1.3, 
95%CI=0.99-2.3, p=0.06, Figure 2.2B), and a modestly higher persistence rate using the two 
consecutive negative definition of clearance (HR=1.6, 95%CI=1.0-2.4, p=0.03, Figure 
2.2D). Results were similar when excluding those individuals with missing intermittent 
infections.   
Factors related to anal and oral HPV persistence 
Adjusted WLW models were used to evaluate factors independently associated with 
anal and oral HPV infection persistence (Table 2.5). Heterosexual males were less likely than 
MSM and women to have a persistent anal HPV (aHR=0.73, 95%CI=0.57-0.92) but not oral 
HPV (aHR=1.4, 95%CI=0.91-2.0, p-interaction=0.02). Age, current tobacco use and current 
and nadir CD4 T cell count at baseline were not associated with anal or oral HPV 
persistence (Table 5). When anal and oral infections were included in the same model, anal 
infections were significantly more likely to persist than oral infections (aHR=1.5, 95% 
CI=1.2-1.9) as were prevalent as compared to incident HPV infections (aHR=4.0, 95% 
CI=3.5-4.8). Risk factors for persistence were similar among the 207 individuals with at least 
two follow-up visits following their first detection of HPV and between oncogenic and non-
oncogenic HPV types (Table 2.6).  In addition, associations between risk factors and 
patterns of persistent HPV infection (calculated using multinomial logistic regression with 
GEE) were similar to the WLW analysis except that the anal HPV persistence pattern was 





 To our knowledge, this is one of the first prospective studies of the natural history of 
anal and oral HPV infection in HIV-infected individuals. The higher prevalence, incidence 
and persistence of anal versus oral HPV infections we observed likely contribute to the 
higher risk of anal as compared to oral HPV-associated cancers in this population.4,5 
The higher prevalence of anal versus oral HPV infections observed in this study is 
consistent with prior reports.10,12,22 Our data indicate that the higher prevalence is due to a 
combination of a considerably higher incidence rate and a modestly higher persistence rate 
of anal as compared to oral HPV infections.  
These data support a hypothesis of an influence of anatomic site of infection on the 
natural history of HPV. Possible factors contributing to the observed differences in 
incidence include variation in the frequency of sexual behaviors related to transmission, local 
mucosal immunity differences such as the continuous flow of saliva and associated 
immunoglobulins in the oral region, sample collection differences and a higher propensity 
for epithelial microtrauma in the anal region.23  The different methods for oral (rinse) as 
compared to anal (swab) sampling might affect detection of persistent infection, however 
research has shown similar rates of HPV type-specific agreement for oral (rinse), anal (swab) 
and cervical (brush) infections with repeat sampling. 14,16,24 
With regard to sexual behavior, the observed incidence of anal HPV infection was 
high among MSM, but also among women and heterosexual men. A high anal HPV 
prevalence among men and women in the absence of receptive anal sex is consistent with 
other recent studies involving HIV-infected11 and HIV-uninfected individuals.25,26 It has been 
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suggested that non-penetrative sexual behaviors and auto-inoculation through HPV 
shedding from vaginal discharge could lead to anal HPV infection.11,26-28 Indeed, HPV type-
specific concordance of anal and genital infections has been observed among heterosexual 
men and women reporting never having anal sex.11,26-28 Similar to another recent study,29 we 
found that anal HPV detected among heterosexual men was less common and less likely to 
persist than in MSM and women. Notably, the incidence of oral HPV infections was higher 
among heterosexual men than MSM and women. This is consistent with the higher 
prevalence of oral HPV infection among men30 as well as higher rates of HPV-associated 
oropharyngeal cancer among men in the U.S..31   
 We observed a large proportion of type-specific infections to have an intermittent 
pattern of detection at both anal and oral sites in this HIV-infected population. Similar 
patterns have been previously reported for cervical HPV in both HIV-infected6 and HIV-
uninfected32,33 individuals. It is unclear as to whether intermittent detection is representative 
of newly acquired infection, reactivation of latent infection or rather limitations in sampling 
or fluctuation of HPV viral loads around the lower limits of assay detection. We 
acknowledge that some of the newly detected infections classified as incident likely represent 
true prevalent infections with intermittent detection. In support of this, incident anal and 
oral HPV infections were observed among individuals who reported no recent anal or oral 
sex. In the cervical literature it remains unclear as to whether or not consistent HPV 
detection versus intermittent HPV detection carries different risks with regard to disease 
progression. However, HIV-infected women with transient cervical HPV infections have a 
fivefold increased risk of pre-cancer compared to women without cervical HPV infection.34     
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Similar to previous studies, baseline oral and anal HPV prevalence was associated with 
reduced CD4 T cell count.11,12 Yet, unlike other anogenital HPV studies,7,29,35,36 persistence of 
oral and anal HPV was not associated with severity of immunosuppression. This difference 
may be explained by our limited sample size or by the fact that the risk factor information 
such as tobacco use and sexual behavior were only collected at baseline. The lack of time 
updated measures limits the interferences between HPV persistence and the risk factors of 
interest as they are prone to unmeasured confounding or time dependent bias.37,38                    
There were several limitations to this study. This population of urban HIV-infected 
MSM, women and heterosexual men posed several challenges to retention including 
relocation, incarceration and death that led to non-optimal loss to follow-up and missing 
intermittent visits. However, those lost to follow-up were similar in baseline characteristics 
(CD4, drug use) to those who continued to participate throughout the study and results were 
similar in the multinomial pattern analysis (restricted to those with 4+ visits) compared to 
the WLW analysis (included all participants). In addition, risk factors were only available at 
study baseline and we have likely underestimated the true prevalence of oral HPV infection 
in the study population by restricting our analysis to the 37 HPV types represented on the 
line blot.39,40 Participants were recruited through a convenience sample and may not reflect 
all HIV-infected individuals in this clinic setting, or the larger HIV-infected community. 
Given the unique aspects of the cohort, including HIV-related immunosuppression and 
heavy drug use, these results should not be generalized to healthier populations.  
The study also had notable strengths. The cohort used well validated statistical and 
laboratory methods7,14,16 to explore for one of the first times, the type specific oral HPV 
natural history, and compare this to anal HPV infection in the same individuals. The study 
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population included individuals with a wide range of CD4, including severely 
immunosuppressed individuals, and included MSM, heterosexual men and women. 
HIV-infected individuals appear able to clear many anal and oral HPV infections, but 
persistent and intermittent infections remain common. Higher anal than oropharyngeal 
cancer rates in HIV-infected individuals may be explained both by higher incidence of 
infection and higher persistence of anal compared to oral HPV infection. Further research is 
needed to better understand the natural history of anal and oral HPV infection including the 
potential impact of screening and the prophylactic HPV vaccines, particularly among these 
groups at greater risk for HPV-associated cancer. 
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Table 2.1 – Baseline characteristics of the 404 participants in this Baltimore, MD based 
study, 2006-2009  
  N % 
Demographics 
Median Age at Baseline [IQR] 46.4 [42.1-51.0] 
Sexual Orientation   
   Men who have sex with men (MSM) 69 18% 
   Heterosexual Men 168 43% 
   Female 153 39% 
Race/Ethnicity   
   African American non-Hispanic 317 82% 
   White non-Hispanic 43 11% 
   Hispanic, Native American, Asian 21 5.40% 
   Other 7 1.80% 
Education   
   < High School Degree 180 46% 
   High School Degree Only 119 31% 
   Some college / college graduate 91 23% 
Drug and Sexual Behavior 
Tobacco Use   
   Never 88 23% 
   Former 34 9% 
   Current 268 69% 
Hard Drug use (any crack, cocaine, or heroin)   
   Never 50 13% 
   Former  182 47% 
   Current  158 41% 
Lifetime Sexual Behavior  
   Ever had receptive anal sex among women 61 40% 
   Number of vaginal partners among women, median (IQR) 8 [3, 20] 
   Number of vaginal partners among heterosexual men, 
median (IQR) 
20 [5, 38] 
   Number of anal sex partners among MSM, median(IQR) 13 (3, 38) 
   Number of oral sex partners performed on, median (IQR) 4 (1, 9) 
   Ever engaged in rimming (oral-anal) 95 26% 
Current (Past Six Months) Sexual Behavior     
   Recent receptive anal sex among women 18 12% 
   Recently had vaginal sex among women 78 51% 
   Recently had vaginal sex among heterosexual men 89 54% 
   Recent receptive anal sex among MSM 29 42% 
   Recently performed oral sex (1 or more partners) 137 35% 
   Always used condoms for vaginal and anal sex 143 40% 
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HIV-Related Biologic Measures    
Nadir CD4 cell count: median [IQR] 169 [62-286] 
   250 or more cells/mL 120 32% 
   100-250 cells/mL 133 35% 
   Less Than 100 cells/mL 128 34% 
Current CD4 T cell count: median [IQR] 304 [183-502] 
   500 or more cells/mL 97 25% 
   200-500 cells/mL 173 45% 
   Less than 200 cells/mL 115 30% 
HIV RNA viral load: median [IQR] 5583 [400, 41635] 
   Less than 400 copies/uL 129 34% 
   401-20,000 copies/uL 108 29% 
   20,000 copies/ul or more 141 37% 
Ever antiretroviral therapy (ART) use    
   No 124 32% 
   Yes 261 68% 
HPV Prevalence at Baseline     
Any HPV (37 types)*     
   Anal HPV 315 84% 
   Oral HPV 108 28% 
Oncogenic HPV (14 types)*     
   Anal HPV 251 67% 
   Oral HPV 51 13% 
HPV16*     
   Anal HPV 77 21% 
   Oral HPV 9 2.3% 
Multiple HPV types*     
   Anal HPV 267 71% 
   Oral HPV  42 11% 
*Comparing anal vs. oral, p-value<0.001     
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Table 2.2 – Risk Factors related to baseline HPV prevalence and incidence by anatomical 
site 
Baseline Characteristics of 
HOPE participants 
Adjusted PR& Adjusted HR& 
  Prevalent Infection at Baseline Incident Infection 
  Anal HPV Oral HPV Anal HPV Oral HPV 
Age         
Aged 20.7-42.1 (quartile 1) REF REF REF REF 
Aged 42.2-46.4 (quartile 2) 0.84 (0.67-1.1) 0.85 (0.47-1.5) 1.2 (0.84-1.7) 1.6 (0.67-3.7) 
Aged 46.5- 51.3(quartile 3) 0.96 (0.78-1.2) 0.92 (0.48-1.8) 0.56 (0.38-0.84) 0.80 (0.40-1.6) 
Aged 51.4-60.2 (quartile 4) 0.67 (0.52-0.86) 0.83 (0.44-1.6) 0.58 (0.37-0.90) 0.78 (0.34-1.8) 
  p-trend=0.004 p-trend=0.38 p-value<0.001^   p-value=0.07^ 
Sexual Orientation         
Female REF REF REF REF 
MSM 0.84 (0.64-1.1) 1.1 (0.57-2.0) 0.89 (0.58-1.4) 1.4 (0.53-3.9) 
Heterosexual Men 0.47 (0.37-0.59)# 1.3 (0.74-2.2)# 0.64 (0.46-0.88)* 2.1 (1.2-3.9)* 
          
Current Tobacco Smoker         
No REF REF REF REF 
Yes 1.2 (1.0-1.4) 1.2 (0.73-2.0) 0.95 (0.68-1.3) 0.72 (0.40-1.3) 
          
Number of Lifetime Anal Sex Partners        
0 (Never) REF   REF   
1 to 5 1.2 (1.0-1.5)   1.3 (0.87-1.8)   
6 or more 1.5 (1.1-2.1)   1.4 (0.78-2.4)   
  p-trend=0.17   p-trend=0.27    
Number of Lifetime Oral Sex Partners        
0 (Never)   REF   REF 
1 to 5   0.73 (0.39-1.4)   0.48 (0.22-1.0) 
6 or more   0.83 (0.38-1.8)   0.94 (0.46-1.9) 
    p-trend=0.73   p-trend=0.86 
Ever Rimming (performed anal-oral)       
No   REF   REF 
Yes   1.1 (0.56-2.2)   0.41 (0.18-0.89) 
    p-trend=0.13    p-trend=0.11 
Number of recent anal sex partners (receptive)       
0 REF   REF   
1 1.3 (1.0-1.7)   0.67 (0.43-1.0)   
2+ 1.2 (0.84-1.6)   1.1 (0.51-2.3)   
  p-trend=0.33    p-trend=0.54   
Number of recent oral sex partners (performed)       
0   REF   REF 
1   1.6 (0.86-2.9)   1.5 (0.70-3.2) 
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2+   1.6 (0.83-3.1)   2.1 (0.87-5.2) 
    p-trend=0.59   p-trend=0.15 
Condom Use for anal or vaginal sex       
Always REF   REF   
Never/Sometimes 1.1 (0.88-1.3)   0.91 (0.68-1.2)   
          
Nadir CD4 T cell count          
>250 cells/mL REF REF REF REF 
100-250 cells/mL 0.89 (0.72-1.1) 0.82 (0.42-1.6) 1.4 (0.94-2.1) 1.7 (0.80-3.4) 
<100 cells/mL 0.84 (0.65-1.1) 1.4 (0.71-2.6) 1.0 (0.63-1.5) 2.2 (0.85-5.7) 
  p-trend=0.98 p-trend=0.23  p-trend=0.44 p-trend=0.10  
Current CD4 T cell count          
>500 cells/mL REF REF REF REF 
200-500 cells/mL 1.4 (1.1-1.7) 1.8 (0.88-3.5) 1.5 (1.1-2.2) 0.69 (0.33-1.5) 
<200 cells/mL 1.6 (1.3-2.1) 1.1 (0.44-2.7) 1.1 (0.71-1.8) 0.49 (0.19-1.3) 
  p-trend=0.002 p-trend=0.18 p-trend=0.12 p-trend=0.82 
^p-value for age and incident infection compares the two young quartiles to the two older quartiles 
*Using a combined prevalent anal and oral model, all tests for interaction between prevalent anal and oral 
infection were>0.05 except the p-interaction for heterosexual males was <0.001 
*Using a combined incident anal and oral model, all tests for interaction between anal and oral incident 
infection were>0.05 except the p-interaction for heterosexual males was <0.001 





Table 2.3 - Incidence Rates of Oral and Anal HPV Infection per 1000 person-months and 
adjusted Hazard Ratios (aHR) for anal compared to oral HPV incidence 
 
  
Incidence Rate (per 1000 
person-months) 
  
  Anal HPV Oral HPV 
Adjusted HR^  
(95% CIs) 
Overall HPV 145 31 4.7 (3.6-6.2) 
   Women (n=153) 184 22 7.6 (5.0-11.6) 
   Men who have sex with men (MSM)(n=69) 165 31 5.7 (2.2-12.4) 
   Heterosexual Men (n=168) 96 38 2.6# (1.8-3.8) 
Oncogenic HPV 60 9.6 6.8 (4.6-10.0) 
Non-oncogenic HPV 85 22 3.9* (2.9-5.3) 
HPV Vaccine Types (6, 11, 16, 18) 17 4.3 4.9 (2.8-8.5) 
HPV16 6.9 1.4 9.7  (3.5-26.8) 
^Hazard Ratios calculated using WLW method adjusting for age, gender/sexual preference, tobacco, 
number of recent sexual (anal/vaginal), number of lifetime sexual partners, nadir and current CD4 T 
cell count 
#p-interaction comparing heterosexual men to MSM and women<0.001 





Figure 2.1 - Patterns of Oral and Anal HPV Infection in the HOPE study^ 
 
^Restricted to the 207 individuals with at least two follow-up visits following their first 





































Table 2.4 - Persistence of Anal and Oral HPV Infections, and prevalence 
ratios (PRs) of anal compared to oral HPV infections 
Type of infection and length of 
persistence 
Single negative test 
for HPV clearance 
Two consecutive negative  tests 




















Prevalent - 6 month persistence 63% 46% 1.4 (1.1-1.7) 77% 63% 1.2 (1.1-1.4) 
Prevalent - 12 month persistence 60% 36% 1.6 (1.3-2.1) 73% 53% 1.4 (1.2-1.6) 
Prevalent - 18 month persistence 50% 27% 1.8 (1.3-2.5) 65% 48% 1.4 (1.1-1.7) 
Prevalent - 24 month persistence 39% 25% 1.5 (1.0-2.3) 58% 47% 1.2 (0.95-1.6) 
Incident - 6 month persistence 38% 32% 1.2 (0.82-1.7) 64% 54% 1.2 (0.91-1.5) 
Incident - 12 month persistence 28% 15% 1.9 (1.1-3.3) 46% 40% 1.2 (0.78-1.7) 
Incident - 18 month persistence 24% 10% 2.4 (0.94-6.2) 36% 28% 1.3 (0.67-2.6) 







Figure 2.2 – Kaplan Meier survival curves comparing the time to clearance of anal vs. oral 
HPV infections, using a single negative (panel A and B) and two consecutive negative (panel 




*Anal (black) and oral (gray) HPV infections are shown. HPV clearance required only one 
negative visit in the top two figures, and required two negative visits in the bottom two 
figures. 
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Table 2.5 – Associations between factors of interest with anal and oral HPV persistence in the 
HOPE Study  




Anal HPV^ Oral HPV^ 
Age     
Aged 20.7-42.1 (quartile 1) REF REF 
Aged 42.2-46.4 (quartile 2) 0.96 (0.73-1.3) 1.1 (0.62-1.9) 
Aged 46.5- 51.3(quartile 3) 0.82 (0.63-1.1) 1.0 (0.56-1.9) 
Aged 51.4-60.2 (quartile 4) 0.86 (0.63-1.2) 0.77 (0.41-1.5) 
  p-trend=0.27 p-trend=0.84 
Sexual Orientation     
Female REF REF 
MSM 0.91 (0.72-1.2) 1.2 (0.70-1.9) 
Heterosexual Men 0.70 (0.54-0.91)* 1.5 (0.90-2.4)* 
      
Type of Infection     
Incident REF REF 
Prevalent 4.4 (3.6-5.4) 3.0 (2.1-4.2) 
      
Current Tobacco Smoker     
No REF REF 
Yes 1.2 (0.92-1.5) 1.0 (0.67-1.6) 
      
Nadir CD4 T cell count      
>250 cells/mL REF REF 
100-250 cells/mL 1.2 (0.90-1.6) 0.87 (0.55-1.4) 
<100 cells/mL 0.76 (1.0-1.4) 1.4 (0.81-2.6) 
  p-trend=0.71 p-trend=0.06 
Current CD4 T cell count      
>500 REF REF 
200-500 1.0 (0.79-1.4) 1.2 (0.70-2.0) 
<200 1.1 (0.80-1.6) 1.2 (0.59-2.3) 
  p-trend=0.77 p-trend=0.09 




*Using a combined persistent anal and oral model, all tests for interaction between persistent anal and oral 
infection were>0.05 except the p-interaction for heterosexual males  (vs. women/MSM) was 0.02 
~Adjusted analysis included anatomical site, age, sexual orientation, type of infection, tobacco use, nadir and 
current CD4 T cell count. 





Table 2.6 - Associations between factors of interest with anal and oral oncogenic HPV 
persistence in the HOPE study 
 
Baseline Characteristics of HOPE participants 
Adjusted HR~ 
Persistent Onc. Infection& 
Anal HPV^ Oral HPV^ 
Age     
Aged 20.7-42.1 (quartile 1) REF REF 
Aged 42.2-46.4 (quartile 2) 1.0 (0.71-1.3) 0.73 (0.15-3.3) 
Aged 46.5- 51.3(quartile 3) 0.91 (0.66-1.3) 1.0 (0.21-5.1) 
Aged 51.4-60.2 (quartile 4) 0.84 (0.56-1.2) 0.73 (0.11-5.0) 
  p-trend=0.32 p-trend=0.84 
Sexual Orientation     
Female REF REF 
MSM 0.75 (0.54-1.0) 1.5 (0.59-3.9) 
Heterosexual Men 0.66 (0.49-0.89)* 1.6 (0.51-5.2)* 
      
Type of Infection     
Incident REF REF 
Prevalent 4.5 (3.4-5.9) 3.0 (1.3-7.1) 
      
Current Tobacco Smoker     
No REF REF 
Yes 1.2 (0.88-1.5) 1.4 (0.65-3.1) 
      
Nadir CD4 T cell count      
>250 cells/mL REF REF 
100-250 cells/mL 1.2 (0.87-1.7) 1.6 (0.54-4.6) 
<100 cells/mL 1.0 (0.62-1.6) 1.7 (0.59-4.8) 
  p-trend=0.87 p-trend=0.18 
Current CD4 T cell count      
>500 REF REF 
200-500 0.93 (0.64-1.3) 1.3 (0.40-4.4) 
<200 1.3 (0.77-2.1) 1.6 (0.43-5.6) 
  p-trend=0.94 p-trend=0.64 
^Using HPV clearance definition of one negative visit   
*In the combined anal and oral HPV model all tests for interaction between persistent anal and oral infection 
were>0.05, the p-interaction for heterosexual males was 0.06 
~Adjusted analysis included age, sexual orientation, type of infection, tobacco use, nadir and current CD4 T 
cell count. 
















  Adj. OR  95% CI Adj. OR 95% CI Adj.OR 95% CI 
Site of Infection            
Oral HPV Infection REF REF REF 
Anal HPV Infection 0.88 (0.49-1.6) 2.0 (1.1-3.7) 2.3 (1.3-3.9) 
            
Type of Infection            
Incident REF REF REF 
Prevalent 2.57 (1.7-4.0) 2.96 (1.94-4.52) 1.15 (0.79-1.67) 
             
Age           
Aged 20.7-42.1 (quartile 1) REF REF REF 
Aged 42.2-46.4 (quartile 2) 0.55 (0.34-0.88) 0.98 (0.58-1.7) 1.4 (0.84-2.3) 
Aged 46.5- 51.3(quartile 3) 0.65 (0.38-1.1) 0.91 (0.52-1.7) 0.95 (0.57-1.6) 
Aged 51.4-60.2 (quartile 4) 0.95 (0.57-1.6) 0.9 (0.50-1.6) 1.4 (0.79-2.5) 
             
Sexual Orientation            
Female REF REF REF 
MSM 0.88 (0.57-1.4) 0.96 (0.60-1.5) 1.1 (0.72-1.7) 
Heterosexual males  0.73 (0.45-1.2)^ 0.56 (0.32-0.99)^ 0.77 (0.48-1.3) 
             
Current Tobacco Use            
No REF REF REF 
Yes 1.3 (0.82-1.9) 1.1 (0.70-1.8) 0.90 (0.56-1.4) 
             
Nadir CD4 cell count             
>250 cells/mL REF  REF  REF 
100-250 cells/mL 1.00 (0.62-1.59) 1.53 (0.82-2.86) 1.54 (0.92-2.58) 
<100 cells/mL 0.69 (0.40-1.19)# 1.14 (0.61-2.12) 1.65 (0.95-2.87)# 
             
Current CD4 T cell count             
>500 cells/mL REF REF  REF  
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200-500 cells/mL 1.38 (0.91-2.1) 1.07 (0.61-1.89) 0.78 (0.48-1.24) 
<200 cells/mL 1.39 (0.76-2.6) 1.36 (0.74-2.51) 0.98 (0.56-1.71) 
^p-interaction<0.05. Heterosexual men were more likely to have oral HPV intermittent and persistent patterns 
than cleared patterns, while they were less likely to have intermittent anal HPV intermittent and persistent 
patterns than a cleared pattern.  
#p-interaction<0.05. Individuals with low nadir CD4 more likely to have intermittent patterns than cleared or 
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Background: Human papillomavirus (HPV) causes the majority of oropharyngeal cancers in 
the United States, and yet the risk factors and natural history of oral HPV infection are 
largely unknown.  
Methods: Semi-annual oral rinses were collected for up to three years (2010-2013) from 761 
HIV-infected and 469 HIV-uninfected participants in the Multicenter AIDS Cohort Study 
and the Women’s Interagency HIV Study. Oral rinses were evaluated for 37 HPV genotypes 
using the Roche linear array. Factors associated with incidence and clearance were explored 
using adjusted Wei-Lin-Weissfeld modeling.  
Results: The cumulative incidence of type-specific oral HPV infection at two-years was 28%. 
HIV-infection (aHR=2.3, 95%CI=1.7-3.2) and severity of immunosuppression (current 
CD4<200: aHR=6.0, 95%CI=2.7-13.3) were associated with increased risk of oral HPV. 
Additionally, increased risk of infection was associated with younger age, no history of 
tonsillectomy, and a larger lifetime number oral sex partners in HIV-infected individuals, and 
with a larger number of recent partners for oral sex, rimming, and performance of oral sex 
on a woman in HIV-uninfected individuals (all p<0.05). Clearance of incident (93%) and 
prevalent (65%) oral HPV infection within two years was common, nevertheless 23% of all 
infections persisted to two-years. Older age, current smoking, and male gender significantly 
reduced clearance rates after adjustment (each p<0.05), whereas HIV-infection and severity 
of immunosuppression did not (p-trend=0.94).  
Conclusions: Severity of immunosuppression and sexual behavior increase risk of oral HPV 
infection whereas male gender, older age and current cigarette smoking increase risk of 
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persistence. This natural history study thus elucidates the consistent associations observed 




Oropharyngeal cancers caused by oral human papillomavirus (HPV) infection have 
increased in incidence over the past several decades, and now represent over half of 
oropharyngeal cancers in the United States (US).1,2 Case-control studies report that oral HPV 
infection greatly increases the odds of oropharyngeal cancer.3,4 Nevertheless, the natural 
history of oral HPV has not been well characterized. 
Cross-sectional studies estimate that 5-8% of individuals in higher income countries 
have an oral HPV infection.5,6 These studies also suggest that prevalent oral HPV infection is 
more common among men, cigarette smokers, HIV-infected individuals, and those with a 
higher number of sexual partners.5,7,8 However, the influence of these factors on the natural 
history of oral HPV infection is largely unexplored. Preliminary longitudinal studies indicate 
that oral HPV infection is infrequent and has a high clearance rate.9,10 Because of a range of 
factors, including short follow-up duration, a limited sample size, and/or high losses to 
follow-up,9-14 the longitudinal studies to date have not adequately identified factors that are 
independently associated with the acquisition of oral HPV and its subsequent clearance.  
For this study, we sought to identify factors independently associated with oral HPV 
incidence and clearance. HIV-infected individuals are a subgroup of particular interest due to 
their higher oral HPV prevalence 7,15 and incidence of HPV-related oropharyngeal cancer.16,17 
Therefore, we studied the natural history of oral HPV among a population of HIV-infected 




Materials and Methods: 
Study Population and Study Design: 
The Persistent Oral human Papillomavirus Study (POPS) is a prospective study 
nested within two ongoing longitudinal studies of HIV-infection: the Multicenter AIDS 
Cohort Study (MACS) and the Women’s Interagency HIV Study (WIHS) which have 
previously been described.7,18,19 A convenience sample of HIV-infected and at risk HIV-
uninfected individuals was enrolled in POPS between October 2009 and March 2011. This 
study stratified enrollment by study site and HIV-status and individuals who were 
combination antiretroviral (cART, also known as HAART) naïve were oversampled to allow 
for a comparison of oral HPV natural history among treated and untreated HIV-infected 
adults. This study’s definition for cART was directed by the US Department of Health & 
Human Services/Kaiser Panel and is defined as the reported use of three or more 
antiretroviral medications, which may consist of a protease inhibitor (PI), an non-nucleoside 
reverse transcriptase inhibitor (NNRTI), one of the nucleoside reverse transcriptase 
inhibitors (NRTIs) such as abacavir or tenofovir, or an integrase or entry inhibitor.20   
Men in the MACS (who were primarily men who have sex with men (MSM)) were 
enrolled from the Chicago, Pittsburgh, and the Baltimore/Washington D.C. sites, whereas 
women from the WIHS (who were primarily heterosexual) were enrolled from the Chicago, 
Brooklyn, and Bronx sites. The POPS protocol was approved by the MACS and WIHS 
executive committees and Institutional Review Boards from each site. All the participants 
provided written informed consent. 
Study participants were followed semi-annually for up to three years (data cut-point: 
March 2013). At each visit, exfoliated epithelial cells from the oral cavity and pharynx were 
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collected by use of a 30 second oral rinse and gargle sample collected using ScopeTM 
mouthwash or saline, as previously described.21,22  Participants underwent a physical 
examination, venipuncture for CD4 T cell count and HIV RNA viral load, and completed 
demographic and behavioral surveys.18,19 At enrollment into POPS, participants also 
completed a POPS-specific risk factor survey that included additional questions such as 
lifetime number of oral sex partners. Risk factor data were collected through computer-
assisted self-interview (CASI) in the MACS and through interview-administered 
questionnaires in the WIHS. 
The study’s definition for the number of oral sex partners included all male or female 
partners on whom the participant performed oral sex on (fellatio or cunnilingus). Rimming was 
defined as “using your mouth on a partner’s anus/butt” (oral-anal contact). Nadir CD4 T 
cell count was defined as the lowest CD4 T cell count observed in an individual during their 
participation in the MACS or WIHS or in their abstracted medical record prior to entrance 
into the MACS or WIHS.  Recent behavior was defined as within the past six months. 
Laboratory Analysis: 
Oral rinse samples were stored at 4º Celsius for up to one week until processed at 
the Gillison laboratory at the Ohio State University. To avoid specimen contamination, strict 
laboratory procedures were adhered to and have been previously described.23 DNA was 
purified from the oral rinse using a magnetic bead-based automated platform 
(QIAsymphony SP, Qiagen), as previously described.24 Purified DNA was then evaluated for 
37 different HPV DNA genotypes utilizing PGMY09/11 PCR primer pools followed by 
reverse line blot hybridization to the RocheTM linear array. Samples were considered 
evaluable if positive for β-globin, while those negative for β-globin were re-tested and 
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excluded from the analysis if the re-test was also β-globin negative. Two lab technicians 
independently interpreted the results; any discrepancies were resolved by the principal 
investigator of the laboratory (Gillison).  
HPV types were classified as either oncogenic (high risk) or non-oncogenic (low risk) 
utilizing criteria from the World’s Health Organization International’s Agency for Research 
on Cancer (IARC).25-27 HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, and 73 
were classified as oncogenic, while HPV types 6, 11, 26, 40, 42, 53, 54, 55, 61, 62, 64, 66, 67, 
69, 70, 71, 72, 81, 82, 83, 84, IS39, and CP6108 were classified as non-oncogenic.  
Statistical Analyses: 
Type specific oral HPV infection was the principal outcome in this study. An 
infection was classified as prevalent if detected at the baseline visit and classified as incident 
if detected after a negative type-specific test at baseline. Clearance of type-specific HPV 
infection was defined in two ways: 1) requiring either a single negative test or 2) requiring 
two consecutive negative tests. Infections that met either definition were considered cleared 
at the time of the first negative test. 
 Participant characteristics by HIV-status and cohort (MACS vs. WIHS) were 
described and compared utilizing chi-square tests for categorical variables and Mann-
Whitney tests for medians for continuous variables. Cumulative incidence curves were 
utilized to explore the incidence of oral HPV, and Kaplan Meier curves were utilized to 
determine the time to clearance of oral HPV. The interval between visits in both MACS and 
WIHS is approximately six months, but the time between visits for participants often varied 
between five and seven months. Therefore, when reporting oral HPV clearance and 
cumulative incidence at six, twelve, and 24 months, individuals with visits within one month 
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of each time point of interest were also included. For infections with missing intermittent 
visits we used the “carry forward” method, which assumes the HPV results were the same at 
the missing intermittent visit as the previous visit. Among the 1,270 detected oral HPV 
infections in this study, 15% of infections had at least one missing intermittent visit, and 4% 
of infections had two or more missing intermittent visits.  
Risk factors were explored using unadjusted and adjusted Wei-Lin-Weissfeld (WLW) 
models.28,29 These marginal models utilize Cox proportional hazard modeling, adjust for the 
correlation between the multiple infections within a single participant, and include an 
exchangeable correlation structure and robust variance. 28,29 In regression modeling, 
covariates that were collected semi-annually in MACS and WIHS were utilized as time-
varying variables when appropriate (e.g. recent number of oral sex partners, smoking status, 
and current CD4). Variables only collected once in the baseline survey (e.g. lifetime number 
of oral sex partners) were included as time-fixed variables in the model.  
The initial adjusted WLW models for incidence and clearance of oral HPV infection 
included variables that were significant (p<0.05) in the unadjusted models and those 
variables considered relevant to oral HPV acquisition and/or clearance based on previous 
literature. Correlation between covariates was calculated through a Pearson’s correlation 
coefficient. Covariates that were strongly correlated with each other (such as oral sex with 
rimming and current and nadir CD4 with HIV viral load) were considered in separate 
models and were evaluated together in the same model when deciding which variables to 
include in the final model (data not shown). Both the clearance and incidence models 
considered interactions by HIV-status and gender/cohort.  
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In a sensitivity analysis to explore intermittently detected HPV type-specific 
infections, we categorized the infections into discrete patterns as: “persistent” if they were 
positive at all the visits following an initial positive, “intermittent” if infections varied 
between negative and positive throughout the study observation, and “cleared” if an 
infection had at least two subsequent negative visits after a positive and did not re-appear at 
a later visit.9 The patterns were then compared using multinomial logistic regression with 
Generalized Estimating Equations (GEE), and “cleared” infections were used as the 
reference. All statistical tests were two sided and considered significant using an alpha=0.05 
level. All analyses were performed by STATA MP Version 12.0 (STATA Corp, College 




During this three year study with semi-annual follow-up, 6,065 oral rinse samples 
were collected from the 1,230 participants who contributed two or more study visits 
(median=5, interquartile range [IQR]=3-6). There were 24 (0.4%) β-globin negative oral 
rinse samples excluded from the analysis. Median follow-up time was 24.4 months 
(IQR=18.4-35.4), and 89% of eligible participants contributed results at the most recent 
visit. 
The characteristics of the 1,230 participants at enrollment are shown in Table 3.1, 
stratified by cohort (gender) and HIV-status. Among these participants, 45% (n=550) were 
men from the MACS, and 55% (n=680) were women from the WIHS. The vast majority of 
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participants were MSM or heterosexual women. Thus, most participants who reported oral 
sex behavior performed the act on a man (fellatio). However, ~5% of both the MACS and 
WIHS participants reported having recently performed oral sex on a woman (cunnilingus). 
When compared to the women from the WIHS, the men from the MACS were older 
(median: 53.7 vs. 46.4 years) and were more likely to be Caucasian, never smokers (41% vs. 
23%), current alcohol drinkers, and more likely to have ever had a tonsillectomy and have a 
greater number of oral sex and rimming partners (each p<0.01, Table 3.1). HIV-infected 
men were significantly more likely than HIV-infected women to be currently using cART 
(87% vs. 74%), to have a higher current CD4 T cell count (median: 575 vs. 520 cells/µL), a 
lower nadir CD4, and a lower HIV RNA viral load (each p<0.01, Table 3.1). 
This study population includes 469 (38%) at-risk HIV-uninfected, 702 (57%) cART-
experienced HIV-infected and 59 (4.8%) cART-naïve HIV-infected individuals. While HIV-
infected and HIV-uninfected participants had many similarities, there were some differences 
in participant characteristics by HIV-status (Table 3.1). HIV-infected individuals were more 
likely than HIV-uninfected participants to be black, not currently drink alcohol, and to have 
a lower number of recent oral sex partners (each p<0.05, Table 3.1).   
Incidence of oral HPV 
Incident, type specific oral HPV infections were commonly observed in the study 
population. The incidence rate of any oral HPV infection was 18.7 infections (95%CI=17.2-
20.3) per 1000 person-months, while the incidence of any oncogenic oral HPV and HPV16 
were 7.3 (95%CI=6.4-8.3) and 1.0 (95%CI=0.72-1.5) per 1000 person-months, respectively. 
After 24 months of follow-up, the cumulative incidence of any type-specific oral HPV, 
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oncogenic oral HPV, and HPV16 were 28% (95%CI=25-31%), 15% (95%CI=12-17%), and 
3.5% (95%CI=2.4-5.0%), respectively.  
Risk factors for incident oral HPV  
Oral HPV incidence was similar between men and women (MACS vs. WIHS: 
IR=19.5 vs. 17.9 per 1000 person-months, p=0.75), but was significantly higher among 
HIV-infected than HIV-uninfected individuals (IR=24.1 vs. 10.3 per 1000 person months, 
p<0.001, Figure 3.1). Further, risk of incident oral HPV infection increased as CD4 T cell 
count declined (p-trend<0.001, Figure 3.1). Additional factors associated with risk of 
incident oral HPV infection in unadjusted analysis included never having had a 
tonsillectomy, younger age, several measures of sexual behavior and HIV-related 
immunosuppression, such as low nadir CD4 T cell count and high HIV RNA viral load 
(Table 3.2-4, each p<0.05). In contrast, gender, current cigarette smoking, marijuana use, 
current cART use, and not always using a condom/dental dam for recent oral sex acts were 
not associated with higher oral HPV incidence (Tables 3.2 & 3.3, each p>0.05). 
After adjustment for demographic and behavioral risk factors,  HIV-infection and 
low current CD4 T cell count were strong risk factors for incident oral HPV infection in 
both the MACS and WIHS (Tables 3.3, 3.5 and Table 3.10, p-trend<0.001). Individuals with 
a current CD4 less than 200 cells/µL had a six-fold higher risk (aHR=6.0, 95%CI=2.7-13.3) 
of incident oral HPV infection than HIV-negative individuals. Current CD4 T cell count was 
associated with risk of incident oral HPV (p-trend=0.01), even after adjusting for correlated 
measures, such as nadir CD4 and HIV viral load. In contrast, low nadir CD4 and a higher 




Number of oral sexual partners was an important determinant of the risk of incident 
infection for both HIV-infected and HIV-uninfected individuals (Table 3.4). Risk of incident 
oral HPV infection increased with higher number of recent partners for oral sex or rimming 
and having recently performed oral sex on a woman among HIV-uninfected individuals, but 
not in HIV-infected individuals (Table 3.4, all p-interactions<0.05). In contrast, risk 
increased with higher number of lifetime oral sex partners among HIV-infected individuals, 
but not HIV-uninfected individuals (although this interaction was not significant, Table 3.4, 
p-interaction=0.76). Number of oral sex partners was strongly correlated with number of 
anal or vaginal sexual partners, and total number of sexual partners for any act (r=0.82). 
Nevertheless, number of recent and lifetime oral sex partners remained significantly 
associated with incident oral HPV risk after adjustment for number of recent and lifetime 
sexual partners for any act (both p-trends<0.01, Table 3.6).  
In addition to immunosuppression and increased number of oral sex partners, risk of 
incident oral HPV remained significantly elevated among younger participants and in those 
never having had a tonsillectomy after adjustment (Table 3.3). All of these associations with 
incident oral HPV infection remained similar when stratifying by gender, with the exception 
that heavy alcohol drinking increased risk of oral HPV infection in the WIHS but reduced 
risk in the MACS (p-interaction<0.001, Table 3.5). Additionally, risk factors for oncogenic 
oral HPV and oral HPV16 incidence were similar to the risk factors for any incident oral 
HPV infection (Table 3.8, all p-interactions>0.05). 
The association between number of lifetime oral sex partners and risk of incident 
oral HPV infection lead us to investigate the possibility of oral HPV re-activation. To do so, 
we stratified participants into whether or not they reported any type of sexual activity over 
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the course of the whole study. The incidence of oral HPV infection among the sexually 
abstinent participants (n=231, 19% of all participants) was only modestly reduced when 
compared to the sexually active group (15.6 vs. 19.4 per 1000 person-months, p=0.26). In 
the sexually abstinent group, HIV-infection, low current CD4, and a higher number of 
lifetime oral sex partners were associated with increased risk of incident oral HPV (data not 
shown). 
An additional subgroup analysis was performed among the 8% (n=58) of HIV-
infected individuals who remained cART naïve throughout the study. Results were similar, 
although the risk of oral HPV infection associated with increasing number of lifetime oral 
sex partners was significantly stronger in cART naïve individuals. (≥100 lifetime partners: 
aHR cART naive=15.1, 95%CI=2.8-81.6 vs. aHR cART experienced=2.7,95%CI=1.2-6.0; p-
interaction=0.01).  
Clearance of oral HPV 
 The majority of incident oral HPV infections cleared within two-years of follow-up. 
When oral HPV clearance was defined by a single negative HPV test, 64% (95%CI=60-
69%) of incident oral HPV infections cleared within six months, and 83% (95%CI=78%-
86%) cleared within a year (Figure 3.2A). One-year clearance rates were similarly high for 
incident oncogenic HPV (81%), HPV16 (83%) and non-oncogenic HPV (83%) types. In 
contrast, only half of prevalent oral HPV infections cleared by one-year (51%, 95%CI=47%-
55%, Figure 3.2B) and these infections were less likely to clear than incident infections 




There were also a considerable number of intermittent infections detected in this 
study, particularly among HIV-infected individuals. Among incident infections with at least 
three follow-up visits, 26% were intermittently detected throughout the study (HIV+: 29%, 
HIV-: 18%, p=0.09), while 11% were persistently detected and 63% cleared. When clearance 
was defined by two negative HPV tests, overall oral HPV clearance rates were appreciably 
lower than when a single negative was used to define clearance (one-year clearance: incident: 
53% vs. 83%, prevalent: 35% vs. 51%; Figures 3.2C and 2D).  
Risk factors for oral HPV clearance  
Men were significantly less likely to clear an incident oral HPV infection when 
compared to women in unadjusted analysis (HR). (One-year clearance rates were 59% vs. 
70%, p=0.002), respectively. Additional factors associated with reduced oral HPV clearance 
in unadjusted analysis including current cigarette use, prevalent oral HPV infection, and 
older age (each p<0.05; Tables 3.2 & Table 3.7). Factors not associated with oral HPV 
clearance in unadjusted analysis included HIV status, current and nadir CD4 T cell count, 
current HIV RNA viral load, marijuana use, cART use, alcohol use, and education (all 
p>0.05, Tables 3.2 & 3.7). 
After adjustment for other factors, older age, male gender and current cigarette 
smoking all remained significantly associated with reduced oral HPV clearance (each p<0.05, 
Table 3.7 & 3.10). In addition, incident infections were significantly more likely to clear than 
prevalent infections (aHR=2.4, 95%CI=2.0-2.8, Tables 3.7 & 3.10). In contrast, HIV-
infection and low current CD4 T cell count remained unassociated with oral HPV clearance 
after adjustment for other risk factors (Table 3.7, p-trend=0.94). Indeed, the lack of 
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association of HIV and current CD4 with oral HPV clearance contrasts with the strong 
association of these factors with oral HPV incidence (Table 3.10). 
In subgroup analyses, risk factor results for oral HPV clearance were similar when 
stratifying by HIV-status (Table 3.7) and between cART naïve and cART experienced 
individuals (all p-interactions>0.05, data not shown). Most of the risk factors for clearance 
were similar between men and women except that reduced oral HPV clearance was 
associated with ever smoking cigarettes in the WIHS only and with lower current CD4 in the 
MACS only (both p-interactions<0.10, Table 3.9). Clearance of oncogenic oral HPV and 
HPV16 were similar to the risk factors for clearance of any oral HPV infection, except older 
age was more strongly associated with reduced clearance of oral HPV16 infection (p-
interaction=0.02, Table 3.8).  
When using a two negative test definition for oral HPV clearance, risk factors for 
clearance were also similar to those observed with a single negative definition (Table 3.10), 
except that HIV-infected individuals were significantly less likely to clear oral HPV than 
HIV-uninfected individuals when using this stricter definition (aHR=0.75, 95%CI=0.60-
0.95). Indeed, in a subsequent analysis where infections were categorized as longitudinal 
patterns, HIV-infected individuals were more likely than HIV-uninfected individuals to have 
an “intermittent pattern” of oral HPV (aOR=1.6, 95%CI=1.0-2.4), but similarly likely to 
have a “persistent pattern” (p=0.18). The associations between the other risk factors and 
patterns of infections, calculated with multinomial logistic regression with GEE, were similar 






  In this natural history study of oral HPV infection, HIV-infection, severity of 
immunosuppression and sexual behavior significantly increased risk of oral HPV infection. 
In contrast, male gender, older age and current cigarette smoking increased risk of oral HPV 
infection persistence. Our data therefore explain in part the consistent associations observed 
between these factors and oral HPV infection in previous cross-sectional studies. 5,7,15,16,30,31  
The majority of incident oral HPV infections, whether oncogenic or non-oncogenic, 
cleared within two years of follow-up. Only 7% of these incident infections persisted to two 
years. The natural history of oral HPV infections is thus quite similar to anogenital HPV 
infections,32-34 where a similar minority of incident infections (~10%) persist to two years. 
The higher persistence rates of prevalent versus incident infections have also been observed 
in the anogenital tract. While anogenital infection persistence is an accepted surrogate for 
subsequent risk of cervical and anal dysplasia, it remains to be determined whether or not 
persistent oral HPV infection could be used to identify those at risk for oropharyngeal 
cancer. 
Surprisingly, our study finds that the higher prevalence of oral HPV infection 
previously observed among immunosuppressed HIV-infected individuals, 7,15,30 is likely 
explained more by an increased incidence of oral HPV rather than a reduced clearance. This 
suggests that immunosuppression may act primarily on the earliest stage of the oral HPV 
carcinogenesis process. The lack of a major impact of immunosuppression on oral HPV 
clearance is counter to most previous studies of cervical HPV clearance,35,36 but more 
consistent with a previous oral HPV9  and a cervical HPV study in the WIHS.33 The lack of 
association with persistence may explain in part the modest increased rate of oropharyngeal 
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cancer in HIV-infected individuals (SIR=1.5-4).16,37 We note, however, that this population 
was relatively immunocompetent and that a modest effect of low CD4 on oral HPV 
clearance among men was observed in our study. Thus, we cannot exclude a possible effect 
of more severe immunosuppression on oral HPV clearance.  
This is one of the first studies to report that performing oral sex and rimming are 
both associated with increased risk of oral HPV acquisition. This differs from a recent study 
among middle aged HIV-uninfected men that reported elevated risk of oral HPV infection 
among single individuals, but not with recent performance of oral sex.10 However, single 
marital status may be a surrogate for new or multiple oral sex partners, as a limitation of 
both studies is the absence of data collection regarding new versus established partnerships. 
While oral sex and rimming are suggested transmitters of oral HPV infection in this study, 
these behaviors are strongly correlated with other sexual behaviors, and we cannot exclude 
the possibility that oral HPV is transmitted in other ways such through autoinoculation of 
anogenital HPV infections.11  
In addition to the association with oral sexual activity, this study suggests that some 
newly detected (incident) oral HPV infections may be re-activated latent infection, similar to 
what has been observed in studies of cervical HPV infection.33,38,39 Along with the quarter of 
infections that were intermittently detected throughout this study, we observed a substantial 
number of incident infections among individuals who self-reported not having any form of 
sex (oral, anal or vaginal) during the study period. In these sexually abstinent individuals, 
there was a strong association of oral HPV incidence with both immunosuppression and a 
higher number of lifetime oral sex partners. Thus, the increased risk of incident oral HPV 
infection among immunosuppressed individuals may be explained by re-activation or re-
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acquisition of previous infection due to poor immune surveillance.40 However, the increased 
risk of oral HPV among HIV-infected individuals may be due in part to increased 
establishment of oral HPV upon exposure. A recent study reported that HIV proteins tat 
and gp120 disrupt the tight junctions in oral and anogenital mucosal epithelium, a factor 
which may facilitate infection.41 
In addition to associations with immunosuppression and sexual behavior, younger 
age and never having a tonsillectomy increased risk of oral HPV infection. To our 
knowledge, this is the first study to find that individuals with a history of tonsillectomy may 
have a reduced incidence of oral HPV infection. However, oral HPV prevalence was similar 
among those with and without a history of tonsillectomy, perhaps due to a non-significantly 
higher persistence of oral HPV in those with a history of tonsillectomy. 
Several factors were associated with reduced clearance of oral HPV infection, 
including cigarette use, older age and male gender. Higher persistence rates among men are 
of particular interest given both the higher oral HPV prevalence 5,30 and incidence rates for 
HPV-positive oropharyngeal cancer among men.42 Reduced oral HPV clearance among men 
is consistent with more vigorous immune response to various infectious agents among 
women when compared to men, potentially due to hormonal differences.43 In addition, the 
higher risk of oral HPV infection we observe among individuals reporting recent oral sex on 
a woman (cunnilingus) (even after adjustment for number of recent and lifetime oral sex 
partners) is consistent with a hypothesis of higher rates of transmission with cunnilingus 
than fellatio. 9,16 This could also contribute to higher oral HPV prevalence and oropharyngeal 
cancer incidence among men. However, as this study included almost exclusively MSM and 
heterosexual women, we are limited in ability to explore these hypotheses further.  
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Our results also suggest that the higher prevalence of oral HPV among cigarette 
smokers,5,7,31 may be due to a reduced ability to clear oral HPV rather than an increased 
likelihood to acquire/re-activate oral HPV. Our association between reduced clearance of 
oral HPV and cigarette smoking was only observed among women, which is consistent with 
an oral HPV prevalence study in the National Health and Nutrition Examination Survey 
(NHANES).5 In addition, our study may help explain oral HPV’s bimodal distribution with 
age, 5 as we suggest that older individuals may have a lower incidence of oral HPV but also a 
reduced clearance.         
Risk factors associated with oral HPV incidence and clearance were similar for non-
oncogenic HPV, oncogenic HPV, and for HPV16 infection alone (which causes more than 
85% of HPV-associated oropharyngeal cancers).44  As over 80% of oral HPV16 infections 
cleared within twelve months in both HIV-infected and HIV-uninfected individuals, a single 
detection of HPV16 would likely have very low specificity for oropharyngeal cancer as it 
does for cervical  intraepithelial neoplasia in higher risk groups.  
This study has several important strengths. It is one of the first large and long-term 
longitudinal natural history studies that provides detailed information on the clearance of 
incident oral HPV infections with high follow-up rates and detailed information on risk 
factors. Previous longitudinal studies have had either little follow-up time, and/or a limited 
number of participants and infections to follow.9-14 In addition, our study population is 
valuable for gaining a better understanding of the natural history of oral HPV given that 
oropharyngeal cancers often occur at middle age and HIV-infected individuals are at 
increased risk for this cancer.16  
83 
 
However, there are also limitations to this study. First, this study population is higher 
risk and has reduced generalizability to other populations. Second, the exact time to 
clearance for oral HPV should be interpreted with caution as our six month sampling 
interval may have underestimated the incidence and clearance rates considering the transient 
nature of oral HPV. On the other hand, type-specific infections were commonly re-detected 
throughout our study so it is also quite possible that using a single negative test overestimates 
the actual clearance rate. As the HPV viral load of some oral infections may have been just 
below the level of detection of the assay, we likely classified some persistent infections as 
cleared when using this single negative test definition. This limitation is true for other HPV 
studies as well, considering oral rinses have shown similar short term percent agreement to 
anogenital sampling.21,24,45 Third, we had some missing data including 15% of infections 
having one missing intermittent visit. However, risk factors for persistence were similar 
when analyzed as multinomial patterns. Finally, we should note that the oral rinses collect 
cells from the oral cavity and pharynx and while they have been shown to have a high 
sensitivity,30 they may have a reduced specificity since it may also identify infections that may 
be less relevant to oropharyngeal cancers.  
This longitudinal study suggests that the risk of incident oral HPV infection is 
increased by sexual behaviors and severity of immunosuppression, while the risk of oral 
HPV persistence is increased by older age, male gender, and current cigarette smoking. We 
find that oral HPV infections are often transient in both HIV-infected and HIV-uninfected 
individuals, but a subset of these infections persist for over two years. The risk that these 
long-term persistent oral HPV infections progress to oropharyngeal cancer is currently 
unclear. Additional research will be necessary to better understand these long-term persistent 
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Table 3.1 – Baseline characteristics by Cohort and HIV-status among 1,230 POPS participants, 2010-
2013 


























    
  White Non-Hispanic 366 (30%) 62%* 3.8%* 26%& 35%& 
  Black Non-Hispanic 682 (55%) 32% 74% 59% 51% 
  Hispanic any race 157 (13%) 4.6% 19% 13% 13% 
  Other race 24 (2.0%) 1.3% 2.5% 2.2% 1.5% 
Study Site 
 
    
  Baltimore/Washington DC 189 (15%) 34% -- 14% 17% 
  Pittsburgh, PA 172 (14%) 31% -- 13% 15% 
  Chicago, IL 398 (32%) 34% 31% 35% 28% 
  Bronx, NY 206 (17%) -- 30% 16% 18% 
  Brooklyn, NY 265 (22%) -- 39% 22% 22% 
Cigarette smoking 
 
    
  Never 381 (31%) 41%* 23%* 31% 32% 
  Former 363 (30%) 31% 29% 29% 30% 
  Current 476 (39%) 28% 48% 40% 37% 
Current alcohol use      
  None 658 (54%) 41%* 64%* 59%& 46%& 
  Less than 2 drinks per day 468 (38%) 46% 32% 35% 43% 
  2 or more drinks per day 97 (8%) 13% 3.8% 6.2% 11% 
Lifetime number of oral sex 
partners (Median, IQR) 10 (3-61) 
61 (30-
224)* 3 (1-10)* 10 (3-61) 10 (3-61) 
  0-4 463 (39%) 13% 59% 40% 39% 
  5 to 99 462 (39%) 40% 38% 38% 40% 
  100 or more 266 (22%) 47% 2.8% 22% 21% 
Number of recent^ oral sex 
partners 0 (0-1) 1 (0-3) 0 (0-1) 0 (0-1) 1 (0-2) 
  0 685 (56%) 35%* 73%* 61%& 49%& 
  1 283 (23%) 26% 21% 21% 26% 
  2 to 5 169 (14%) 25% 5.4% 11% 18% 
  6 or more 77 (6.3%) 14% 0.2% 6.1% 6.7% 
Recent^ oral sex on a woman      
  No 
1,173 
(95%) 94% 95% 97% 93% 
  Yes 62 (5.0%) 5.6% 4.9% 3.3% 6.8% 
Number of recent^ rimming partners     
  None 755 (81%) 70%* 93%* 81% 80% 
  One 101 (11%) 15% 5.9% 10% 13% 
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  Two or more 78 (8.4%) 14% 1.6% 9.0% 7.5% 
Received HPV Vaccine by baseline visit     
  No 
1083 
(91.2%) 90% 92% 89% 95% 
  Yes 27 (2.3%) 1.9% 2.5% 2.8% 1.4% 
  Unsure 77 9 (6.5%) 8.1% 5.2% 8.0% 4.1% 
Ever had a tonsillectomy      
  No 891 (75%) 59%* 87%* 75% 75% 
  Yes 278 (23%) 39% 11% 23% 24% 
  Unsure 19 (1.6%) 2.1% 1.1% 1.8% 1.1% 
Recent frequency of toothbrushing     
  2 or more times per day 707 (59%) 56% 62% 57% 63% 
  1 time per day 368 (31%) 35% 28% 31% 29% 
  <1 time per day 56 (4.7%) 6.1% 3.6% 5.3% 3.6% 
  No teeth/dentures 65 (5.4%) 3.4% 7.0% 5.7% 5.1% 
cART use 
 
    
  Current 604 (79%) 87%* 74%* 79% --- 
  Former 98 (13%) 8.6% 16% 13% --- 
  Never (cART naïve) 58 (7.6%) 4.6% 10% 7.6% --- 












  500 or more cells/µL 424 (56%) 60% 53% 56% 96%* 
  200-499 cells/µL 262 (35%) 34% 35% 35% 4.1%* 
  less than 200 cells/µL 72 (9.5%) 5.5% 12% 10% 0%* 












  500 or more cells/µL 130 (17%) 17% 18% 17% 73% 
  200-499 cells/µL 409 (55%) 55% 54% 55% 26% 
  Less than 200 cells/µL 210 (28%) 28% 28% 28% 0.9% 








  Less than 50 copies/mL 485 (64%) 75% 57% 64% --- 
  50-20,000 copies/mL 192 (25%) 18% 31% 25% --- 
  20,000 or more copies/mL 77 (10%) 7.7% 12% 10% --- 
Number of visits contributed 
 
    
  2 to 3 221 (18%) 17% 18% 18% 17% 
  4 to 5 555 (44%) 39% 49% 44% 46% 
  6 to 7 476 (38%) 43% 33% 39% 37% 
*Factor significantly different between MACS and WIHS participants (p<0.05) 
&Factor significantly different between HIV-infected and HIV-uninfected participants (p<0.05) 
^Recent was defined as behavior in the past six month 
#Restricting to HIV-infected individuals  
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Figure 3.1 – Cumulative Incidence of Any Oral HPV Infection by HIV status and CD4 T cell count 
in the POPS 
 
 
*p-trend is testing oral HPV incidence by HIV-status and CD4 T cell count using  
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Table 3.2: Unadjusted associations between risk factors and oral HPV clearance and incidence by 
gender in the POPS 
Characteristics of POPS 
participants 









HIV-status         
Negative REF REF REF REF 
Positive 0.90 (0.71-1.1) 0.95 (0.69-1.3) 2.1 (1.5-3.0) 2.7 (1.6-4.5) 
Age          
Younger than 45 REF REF REF REF 
45-55 0.93 (0.72-1.2) 0.67 (0.46-0.98) 0.71 (0.41-1.2) 0.91 (0.51-1.6) 
55 or older 0.72 (0.54-0.96) 0.57 (0.38-0.85) 0.54 (0.30-0.95) 0.73 (0.38-1.4) 
p-trend 0.02 <0.001 0.02 0.68 
Race/Ethnicity     
White Non-Hispanic REF REF REF REF 
Black Non-Hispanic 1.2 (0.97-1.6) 1.3 (0.88-1.8) 1.8 (1.2-2.6) 1.1 (0.62-2.2) 
Hispanic any race 0.85 (0.41-1.8) 1.2 (0.79-1.8) 1.5 (0.60-3.7) 0.45 (0.23-0.89) 
Other race 1.8 (1.3-2.4) 2.4 (1.0-5.5) 0.94 (0.30-3.0) 0.50 (0.16-1.5) 
Education         
Less than high school degree REF REF REF REF 
High school degree only REF 1.1 (0.90-1.5) 1.3 (0.56-3.1) 0.70 (0.47-1.0) 
Some college or college degree 0.95 (0.77-1.2) 1.3 (0.82-2.1) 0.79 (0.31-2.0) 1.3 (0.66-2.5) 
More than a college degree 0.92 (0.68-1.2) --- 0.63 (0.24-1.6) --- 
p-trend 0.39 0.23 0.02* 0.54 
p-interaction 0.27 0.18 
Cigarette smoking         
Never REF REF REF REF 
Former 0.89 (0.68-1.2) 0.38 (0.18-0.80) 0.77 (0.54-1.1) 1.1 (0.31-4.0) 
Current 0.94 (0.72-1.3) 0.36 (0.17-0.77) 0.98 (0.66-1.4) 1.6 (0.45-5.5) 
p-interaction 0.03 0.48 
Current cigarette dose        
None REF REF REF REF 
0.1 to 0.49 packs/day 1.0 (0.74-1.4) 0.70 (0.48-1.0) 1.1 (0.64-1.7) 1.5 (0.82-2.7) 
0.5-0.99 packs/day 1.1 (0.78-1.4) 0.80 (0.53-1.2) 1.2 (0.80-1.9) 1.5 (0.81-2.9) 
1 or more packs/day 1.1 (0.79-1.5) 0.73 (0.46-1.2) 1.4 (0.75-2.6) 1.5 (0.74-3.1) 
p-trend 0.59 0.22 0.23 0.14 
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Current alcohol use         
No REF REF REF REF 
Yes (less than 2 drinks per day) 1.0 (0.85-1.3) 1.0 (0.82-1.2) 0.75 (0.56-1.0) 1.2 (0.89-1.5) 
Yes (2 or more drinks per day) 1.1 (0.76-1.7) 1.7 (0.72-3.9) 0.46 (0.26-0.79) 3.1 (1.2-8.1) 
p-trend 0.53 0.40 0.02 0.53 
p-interaction 0.36 0.001 
Current hard drug use        
No REF REF REF REF 
Yes 1.0 (0.78-1.4) 0.83 (0.60-1.2) 1.3 (0.88-1.8) 1.7 (1.1-2.8) 
Current Marijuana Use        
No REF REF REF REF 
Yes 0.93 (0.74-1.2) 0.95 (0.72-1.2) 0.92 (0.68-1.3) 1.1 (0.73-1.8) 
Recent oral sex partners        
0 ---- ---- REF REF 
1 ---- ---- 0.64 (0.44-0.95) 0.93 (0.72-1.2) 
2 to 5 ---- ---- 1.1 (0.77-1.6) 1.7 (0.97-2.9) 
6 or more ---- ---- 1.4 (0.91-2.1) ---- 
p-trend ---- ---- 0.004 0.97 
p-interaction ---- ---- 0.39 
Recent oral sex on a woman     
No   REF REF 
Yes   1.5 (0.84-2.7) 1.8 (0.83-3.9) 
Lifetime oral sex partners        
0 to 4 ---- ---- REF REF 
5 to 99 ---- ---- 1.0 (0.54-1.9) 2.1 (1.3-3.5) 
100 or more ---- ---- 1.4 (0.84-2.4) 3.0 (1.3-7.2) 
p-trend ---- ---- 0.11 0.01 
p-interaction ---- ---- 0.15 
Recent rimming         
No ---- ---- REF REF 
Yes - 1 partner ---- ---- 0.72 (0.45-1.2) 1.2 (0.55-2.4) 
Yes - 2+ partners ---- ---- 1.6 (1.1-2.4) 1.7 (0.55-5.3) 
p-trend    0.02 0.81 
Used condom/dental dams for oral sex%      
No  ---- ---- REF REF 
Yes (always) ---- ---- 1.7 (0.96-2.9) 1.0 (0.50-1.9) 
Site location        
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Baltimore (MACS) REF ---- REF ---- 
Chicago (MACS) 1.1 (0.82-1.4) ---- 1.3 (0.87-2.0) ---- 
Pittsburgh (MACS) 0.93 (0.71-1.2) ---- 0.62 (0.41-0.94) ---- 
Chicago (WIHS) ---- REF ---- REF 
Bronx (WIHS) ---- 0.83 (0.55-1.2) ---- 0.50 (0.28-0.89) 
Brooklyn (WIHS) ---- 0.84 (0.54-1.3) ---- 0.42 (0.23-0.75) 
Ever had a tonsillectomy     
No REF REF REF REF 
Yes 0.79 (0.60-1.0) 0.75 (0.56-1.0) 0.44 (0.31-0.63) 0.96 (0.58-1.6) 
Unsure 0.88 (0.64-1.2) 0.87 (0.58-1.3) 1.1 (0.45-2.5) 1.3 (0.32-5.5) 
Recent tooth brushing     
2 or more times per day REF REF REF REF 
1 time per day 1.2 (0.86-1.6) 0.69 (0.43-1.1) 1.3 (0.90-1.9) 1.3 (0.71-2.3) 
<1 time per day 0.86 (0.45-1.6) 0.87 (0.46-1.7) 1.0 (0.49-2.2) 2.8 (1.5-5.3) 
No teeth/dentures 1.4 (1.1-1.9) 0.29 (0.15-0.58) 1.0 (0.36-2.8) 1.5 (0.78-2.9) 
Current CD4 T cell count        
>500 cells/µL REF REF REF REF 
200-499 cells/µL 0.91  (0.69-1.2) 1.0 (0.85-1.2) 1.5 (1.0-2.2) 1.3 (0.92-1.8) 
<200 cells/µL 0.65 (0.46-0.94) 1.7 (0.99-3.0) 2.3 (1.2-4.4) 4.4 (2.0-9.9) 
p-trend 0.09 0.12 0.002 0.02 
p-interaction 0.005 0.21 
Nadir CD4 T cell count         
500 or more cells/µL REF REF REF REF 
200-499 cells/µL 1.2 (0.81-1.7) 1.1 (0.70-1.6) 1.1 (0.70-1.9) 1.1 (0.61-1.9) 
200-350 cells/µL 0.90 (0.70-1.2) 1.0 (0.70-1.5) 1.9 (1.2-3.0) 1.6 (0.67-3.8) 
<200 cells/µL 0.83 (0.54-1.3) 0.76 (0.56-1.0) 1.6 (0.96-2.6) 1.5 (0.84-2.7) 
p-trend 0.10 0.91 0.02 0.19 
HIV RNA viral load*        
Less than 50 copies/uL REF REF REF REF 
50-20,000 copies/uL 1.1 (0.83-1.3) 1.0 (0.83-1.2) 1.4 (1.0-1.8) 1.4 (1.0-1.8) 
20,000 or more copies/uL 0.93 (0.66-1.3) 1.4 (0.74-2.8) 2.7 (1.2-5.7) 3.5 (1.3-9.3) 
p-trend 0.20 0.33 0.26 0.02 
cART use        
Current  REF REF REF REF 
Former 0.82 (0.55-1.2) 1.7 (0.90-3.4) 1.3 (0.71-2.2) 2.2 (0.81-6.1) 
Never (Naïve) 1.4 (0.97-1.9) 0.80 (0.59-1.1) 1.4 (0.75-2.5) 0.70 (0.34-1.4) 
^1 negative definition of clearance 
%among those performing oral sex 
*less education and current hard drug use was associated with oral HPV incidence in the unadjusted model in 
one of the cohorts, but not the other. These variables were not significant in the combined unadjusted model 




Table 3.3 – Risk Factors related to oral HPV incidence stratified by HIV-status in the POPS 
Characteristics of POPS 
participants 
HIV-infected HIV-uninfected 
Unadjusted HR Adjusted HR~ Unadjusted HR Adjusted HR~ 
CD4 T cell count       
Positive CD4>500 cells/µL REF REF -- -- 
Positive CD4 200-499 cells/µL 1.4 (1.1-1.8) 1.4 (1.1-1.7) -- -- 
Positive CD4<200 cells/µL 3.5 (1.8-6.5) 3.5 (1.7-7.3) -- -- 
p-trend 0.007 0.01 -- -- 
Age     
Younger than 45 REF REF REF REF 
45-55 0.67 (0.41-1.1) 0.77 (0.52-1.1) 1.6 (0.83-3.1) 1.2 (0.62-2.4) 
55 or older 0.59 (0.35-1.0) 0.59 (0.38-0.91) 1.2 (0.64-2.4) 1.1 (0.49-2.4) 
p-trend 0.03 0.01^ 0.61 0.84^ 
Gender    
Female (WIHS) REF REF REF REF 
Male (MACS) 1.1 (0.73-1.5) 1.3 (0.74-2.2) 1.4 (0.85-2.3) 2.3 (0.87-6.3) 
Cigarette smoking     
Never REF REF REF REF 
Former 0.77 (0.45-1.3) 0.75 (0.39-1.4) 1.1 (0.64-2.1) 1.1 (0.64-1.7) 
Current 1.1 (0.64-1.9) 0.86 (0.42-1.8) 1.2 (0.74-2.1) 1.0 (0.56-1.8) 
Current alcohol drinking     
None REF REF REF REF 
Less than 2 per day 1.1 (0.86-1.3) 0.98 (0.78-1.2) 1.0 (0.67-1.5) 0.94 (0.61-1.4) 
2 or more per day 1.2 (0.59-2.5) 1.2 (0.46-3.0) 0.80 (0.39-1.6) 0.74 (0.34-1.6) 
Ever had a tonsillectomy    
No REF REF REF REF 
Yes 0.58 (0.41-0.81) 0.62 (0.44-0.87) 0.71 (0.41-1.3) 0.74 (0.41-1.3) 
Unknown 1.1 (0.49-2.7) 0.86 (0.35-2.1) 1.5 (0.53-4.0) 0.97 (0.27-3.5) 
~Incidence models adjusted for HIV-status, current CD4 T cell count, age, cigarette smoking, alcohol use, 
study site, history of tonsillectomy, recent tooth brushing, and lifetime and recent number of oral sex partners, 
and recent oral sex on a woman 
^p-interaction tests were evaluated between HIV+ and HIV- individuals in adjusted model all were less than 







Table 3.4 – Relationship of sexual behavior and oral HPV incidence stratified by HIV-status in the 
POPS 
Sexual Behavior 
Unadjusted HR Adjusted HR~ Unadjusted HR Adjusted HR~ 
HIV-infected HIV-uninfected 
Recent oral sex partners~     
0 REF REF REF REF 
1 0.91 (0.72-1.2) 0.84 (0.66-1.1) 0.91 (0.60-1.4) 0.84 (0.60-1.2) 
2 to 5 1.4 (0.99-2.0) 1.2 (0.86-1.7) 1.6 (0.97-2.6) 1.4 (0.93-2.1) 
6 or more 1.2 (0.75-2.0) 1.1 (0.62-1.9) 2.7 (1.5-4.6) 2.3 (1.1-4.8) 
p-trend 0.93 0.44 <0.001 <0.001 
p-interaction& 0.05 
Recent oral sex with on a woman#     
No REF REF REF REF 
Yes 1.3 (0.67-2.6) 1.0 (0.54-1.8) 3.2 (1.7-6.1) 3.6 (1.8-7.0) 
p-interaction& 0.03 
Recent number of rimming partners#     
None REF REF REF REF 
One 0.72 (0.43-1.2) 0.72 (0.42-1.2) 1.3 (0.68-2.5) 1.7 (0.83-3.3) 
Two or more 1.3 (0.81-2.1) 1.2 (0.73-1.9) 2.7 (1.5-5.0) 1.6 (0.80-3.1) 
p-trend 0.96 0.92 <0.001 0.02 
p-interaction& 0.04 
Lifetime number of oral sex partners    
0-4 REF REF REF REF 
5 to 99 1.7 (1.1-2.7) 2.2 (1.2-4.0) 1.5 (0.82-2.7) 1.3 (0.70-2.5) 
100 or more 1.8 (1.3-2.5) 2.9 (1.6-5.2) 1.8 (1.0-3.4) 1.8 (0.80-4.3) 
p-trend <0.001 0.01 0.04 0.46 
p-interaction& 0.76 
~The recent oral sex partners association adjusts for lifetime oral sex partners, recent oral sex on a 
woman and other factors in table 2, but does not adjust for recent rimming partners due to their 
collinearity (r=0.60). When including rimming in the model the associations between oral HPV 
incidence were similar but attenuated 
&P-interaction tests examines the interaction between HIV-infected and HIV-uninfected individuals 
in adjusted analyses 
#Recent oral sex on a woman and rimming (oral-anal) partners associations adjust for recent and 





Table 3.5: Risk Factors related to oral HPV incidence by gender and HIV-status 
Characteristics of POPS 
participants 
Adjusted HR (95%CI) 
HIV+ MACS HIV+ WIHS HIV- MACS HIV- WIHS 
CD4 T cell count     
>500 cells/µL REF REF --- --- 
200-499 cells/µL 1.4 (1.0-1.9) 1.3 (0.93-1.8) --- --- 
<200 cells/µL 1.9 (1.1-3.3) 4.6 (1.9-11.3) --- --- 
p-trend 0.03 0.04 --- --- 
Age       
Younger than 45 REF REF REF REF 
45-55 0.71 (0.41-1.2) 0.86 (0.56-1.3) 0.73 (0.27-2.0) 1.4 (0.68-2.9) 
55 or older 0.50 (0.27-0.93) 0.79 (0.49-1.3) 0.71 (0.26-2.0) 1.5 (0.64-3.8) 
p-trend 0.02 0.20 0.52 0.62 
Cigarette smoking     
Never REF REF REF REF 
Former 0.84 (0.56-1.2) 0.74 (0.22-2.5) 0.88 (0.52-1.5) 2.0 (0.58-7.0) 
Current 0.74 (0.45-1.2) 0.98 (0.30-3.2) 0.88 (0.44-1.8) 1.5 (0.43-5.2) 
Ever had a tonsillectomy     
No REF REF REF REF 
Yes 0.48 (0.31-0.72) 0.84 (0.47-1.5) 0.70 (0.38-1.3) 0.85 (0.21-3.4) 
Unknown 1.1 (0.41-2.7) 0.79 (0.49-1.3) 1.1 (0.41-3.1) --- 
Current alcohol use     
No REF REF REF REF 
Less than 2 per day 0.80 (0.58-1.1) 1.1 (0.83-3.8) 0.74 (0.46-1.2) 1.1 (0.63-1.9) 
Two or more per day 0.47 (0.25-0.87) 3.3 (2.0-5.6) 0.54 (0.20-1.4) 1.1 (0.43-2.7) 
Recent oral sex partners     
0 REF REF REF REF 
1 0.67 (0.47-0.95) 1.1 (0.85-1.5) 1.0 (0.60-2.8) 0.82 (0.50-1.4) 
2 to 5 1.1 (0.80-1.6) 1.7 (1.0-2.8) 1.7 (0.95-3.0) 1.4 (0.88-2.3) 
6 or more 1.1 (0.63-1.8) --- 3.0 (1.3-6.7) --- 
p-trend 0.64 0.44 <0.001 0.97 
Recent oral sex on a woman     
No REF REF REF REF 
Yes 1.3 (0.52-3.2) 0.86 (0.40-1.8) 2.8 (1.1-7.2) 4.2 (1.8-10.2) 
Lifetime number of oral sex partners    
0-4 REF REF REF REF 
5 to 99 1.8 (0.85-3.8) 2.0 (0.96-4.0) 0.80 (0.26-2.5) 1.6 (0.75-3.3) 
100 or more 2.3 (1.2-4.4) 3.0 (1.5-6.0) 1.2 (0.33-4.2) 1.0 (0.34-3.5) 
p-trend 0.004 0.01 0.60 0.26 
Recent rimming partners^     
0 REF REF REF REF 
1 0.68 (0.36-1.3) 1.0 (0.36-3.0) 1.1 (0.45-2.5) 
4.6 (1.9-11.3) 




^Rimming results adjust for oral sex partners and other risk factors. However, results for the other risk factors 





Table 3.6: Relationship of sexual behavior and oral HPV incidence stratified by HIV-status including 
adjustment for recent and lifetime number of any sexual partners  
^Incidence models adjusted for HIV-status, current CD4 T cell count, age, cigarette smoking, alcohol use, 
study site, history of tonsillectomy, recent tooth brushing, and lifetime and recent number of oral sex partners, 









Recent oral sex partners         
0 REF REF REF REF 
1 0.91 (0.72-1.2) 0.74 (0.56-1.0) 0.91 (0.60-1.4) 0.75 (0.49-1.1) 
2 to 5 1.4 (0.99-2.0) 1.0 (0.58-1.9) 1.6 (0.97-2.6) 1.1 (0.52-2.2) 
6 or more 1.2 (0.75-2.0) 0.66 (0.30-1.5) 2.7 (1.5-4.6) 2.0 (0.66-6.1) 
p-trend 0.93 0.38 <0.001 <0.001 
Recent sex partners (oral, anal, vaginal)       
0 REF REF REF REF 
1 1.2 (0.80-1.9) 1.3 (0.86-1.9) 0.82 (0.48-1.4) 1.2 (0.69-2.0) 
2 to 5 1.5 (1.0-2.3) 1.3 (0.65-2.7) 1.5 (0.84-2.7) 1.5 (0.68-3.4) 
6 or more 1.5 (0.97-2.5) 2.0 (0.92-4.3) 2.0 (1.1-3.8) 1.2 (0.45-3.1) 
p-trend 0.72 0.21 <0.001 0.42 
Recent oral sex with on a woman        
No REF REF REF REF 
Yes 1.3 (0.67-2.6) 0.93 (0.48-1.8) 3.2 (1.7-6.1) 3.7 (2.0-7.1) 
Lifetime number of oral sex partners        
0-4 REF REF REF REF 
5 to 99 1.7 (1.1-2.7) 2.1 (1.1-4.0) 1.5 (0.82-2.7) 1.6 (0.70-3.8) 
100 or more 1.8 (1.3-2.5) 2.7 (1.3-5.6) 1.8 (1.0-3.4) 2.7 (0.63-11.3) 
p-trend <0.001 0.009 0.04 0.18 
Lifetime number of any sex partners       
0-4 REF REF REF REF 
5-19 1.4 (0.76-2.5) 1.3 (0.86-2.1) 1.4 (0.55-3.3) 1.0 (0.46-2.6) 
20-99 1.2 (0.80-1.8) 1.0 (0.59-1.7) 1.0 (0.39-2.8) 0.73 (0.24-2.2) 
100 or more 1.4 (0.99-2.1) 1.0 (0.54-1.9) 1.5 (0.60-3.6) 0.77 (0.22-2.7) 
p-trend 0.25 0.78 0.47 0.54 
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Figure 3.2 – Clearance of incident (panels A&C) and prevalent (panels B&D) oral HPV infection 
comparing HIV-infected and HIV-uninfected individuals, when a single negative (panels A&B) or 
two consecutive negatives (panels C&D) were required for the definition of clearance in the POPS. 
  
                                                                       
*HR=Hazard Ratios comparing oral HPV clearance comparing HIV-infected to HIV-uninfected 
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Table 3.7 – Risk Factors related to oral HPV clearance stratified by HIV-status in the POPS 
Characteristics of POPS 
participants 
HIV-infected HIV-uninfected 
Unadjusted HR Adjusted HR~ Unadjusted HR Adjusted HR~ 
CD4 T cell count^         
Positive CD4>500 cells/µL REF REF --- --- 
Positive CD4 200-499 
cells/µL 
0.96 (0.81-1.1) 0.98 (0.83-1.2) --- --- 
Positive CD4<200 cells/µL 1.3 (0.79-2.2) 1.1 (0.74-1.7) --- --- 
p-trend 0.52 0.94 --- --- 
Age         
Younger than 45 REF REF REF REF 
45-55 0.77 (0.55-1.1) 0.87 (0.67-1.1) 0.59 (0.41-0.84) 0.60 (0.43-0.85) 
55 or older 0.61 (0.43-0.88) 0.82 (0.61-1.1) 0.45 (0.31-0.63) 0.52 (0.35-0.77) 
p-trend 0.003 0.18 <0.001 0.001 
Gender         
Female (WIHS) REF REF REF REF 
Male (MACS) 0.72 (0.57-0.92) 0.68 (0.51-0.90) 0.75 (0.56-1.0) 0.79 (0.57-1.1) 
Type of infection         
Prevalent REF REF REF REF 
Incident 2.6 (2.1-3.2) 2.5 (2.1-3.0) 2.2 (1.6-3.2) 2.2 (1.5-3.3) 
Cigarette smoking^         
Never REF REF REF REF 
Former 0.80 (0.53-1.2) 0.72 (0.48-1.1) 0.92 (0.63-1.3) 0.78 (0.54-1.1) 
Current 0.86 (0.57-1.3) 0.67 (0.41-1.1)* 0.89 (0.62-1.3) 0.75 (0.49-1.1)* 
Ever had a tonsillectomy         
No REF REF REF REF 
Yes 0.72 (0.56-0.92) 0.83 (0.64-1.1) 0.79 (0.56-1.1) 1.0 (0.69-1.4) 
Unknown 0.86 (0.63-1.2) 1.0 (0.72-1.4) 0.36 (0.15-0.82) 0.42 (0.30-0.60) 
~Adjusted for current CD4 T cell count, age, gender, type of infection, cigarette smoking, history of 
tonsillectomy 
^Effect modification by gender/cohort (p-interaction<0.10, Supp. Table 
4)    
*When HIV-infected and HIV-uninfected individuals were combined, oral HPV clearance was significantly 
lower in current smokers (p<0.05, Table 5).  





Table 3.8: Risk Factors for Oncogenic Oral HPV and Oral HPV16 Clearance and Incidence in the 
POPS 
Characteristics of POPS 
participants 






HIV-status + Current  
CD4         
Negative REF REF REF REF 
Positive CD4>500 cells/µL 0.93 (0.70-1.2) 0.55 (0.24-1.2) 1.5 (0.98-2.2) 1.3 (0.51-3.2) 
Positive CD4 200-499 cells/µL 0.89 (0.65-1.2) 0.64 (0.32-1.3) 1.9 (1.3-3.0) 1.9 (0.73-5.2) 
Positive CD4<200 cells/µL 0.88 (0.52-1.5) 0.65 (0.27-1.6) 5.9 (2.7-12.8) 5.4 (1.9-15.4) 
p-trend 0.56 0.39 <0.001 0.009 
Age         
Younger than 45 REF REF REF REF 
45-55 0.96 (0.68-1.3) 0.41 (0.20-0.83) 0.85 (0.55-1.3) 0.67 (0.34-1.3) 
55 or older 0.72 (0.50-1.0) 0.19 (0.08-0.45)^ 0.56 (0.34-0.93) 0.50 (0.15-1.6) 
p-trend 0.10 0.001 0.01 0.05 
Gender         
Female (WIHS) REF REF REF REF 
Male (MACS) 0.54 (0.39-0.74) 0.52 (0.26-1.1) 1.5 (0.78-2.9) 0.83 (0.17-4.0) 
Type of Infection         
Prevalent REF REF ---- ---- 
Incident 2.6 (2.0-3.3) 4.7 (2.5-8.7) ---- ---- 
Cigarette smoking         
Never REF REF REF REF 
Former 0.80 (0.53-1.2) 1.1 (0.43-2.6) 0.80 (0.45-1.4) 1.0 (0.28-3.5) 
Current 0.55 (0.34-0.90) 0.63 (0.24-1.6) 0.87 (0.46-1.6) 2.4 (0.84-6.6) 
Ever had a tonsillectomy     
No REF REF REF REF 
Yes 0.72 (0.52-1.0) 0.85 (0.42-1.7) 0.70 (0.45-1.1) 1.3 (0.39-4.5) 
Unsure 0.87 (0.56-1.3) ---- 1.7 (0.75-4.0) 1.1 (0.18-7.0) 
Current alcohol Use        
No    REF REF 
Less than 2 per day    0.91 (0.69-1.2) 0.66 (0.34-1.3) 
Two or more per day    1.1 (0.57-2.2) 0.76 (0.27-2.2) 
Recent oral sex partners         
0     REF REF 
1     0.76 (0.55-1.0) 1.1 (0.56-2.2) 
2 to 5     1.2 (0.81-1.8) 1.6 (0.72-3.5) 
6 or more     1.3 (0.78-2.3) 0.74 (0.14-4.0) 
p-trend     0.56 0.19 
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Recent oral sex on a woman     
No   REF REF 
Yes   1.7 (1.0-3.0) 0.92 (0.19-4.5) 
Lifetime number of oral sex 
partners         
0-4     REF REF 
5 to 99     2.3 (1.3-4.2) 3.0 (1.1-8.1) 
100 or more     3.4 (1.7-6.6) 8.0 (2.1-30.3) 
p-trend     <0.001 0.002 
^for older age, p-interaction between HPV16 and non HPV16 




Table 3.9: Risk Factors related to oral HPV clearance in adjusted analyses, stratified by gender and 
HIV-status in the POPS 
^p-interaction for CD4 T cell count between MACS and WIHS is 0.07 





Adjusted HR (95%CI) 
HIV+ MACS HIV+ WIHS HIV- MACS HIV- WIHS 
CD4 T cell count     
>500 cells/µL REF^ REF^ --- --- 
200-499 cells/µL 0.99 (0.76-1.3) 1.0 (0.84-1.2) --- --- 
<200 cells/µL 0.54 (0.37-0.78) 1.6 (1.1-2.2) --- --- 
p-trend 0.001 0.04 --- --- 
Age*       
Younger than 45 REF REF REF REF 
45-55 1.0 (0.77-1.4) 0.91 (0.70-1.2) 0.54 (0.31-0.94) 0.63 (0.39-1.0) 
55 or older 0.87 (0.58-1.3) 0.89 (0.61-1.3) 0.58 (0.36-0.95) 0.44 (0.22-0.87) 
p-trend 0.74 0.28 0.30 0.04 
Type of infection     
Prevalent REF REF REF REF 
Incident 2.5 (1.9-3.3) 2.5 (2.0-3.1) 2.6 (1.7-4.1) 1.9 (0.97-3.6) 
Cigarette smoker*     
Never REF* REF* REF REF 
Former 0.93 (0.67-1.3) 0.43 (0.26-0.71) 0.72 (0.47-1.1) 0.71 (0.29-1.7) 
Current 1.0 (0.74-1.4) 0.38 (0.26-0.71) 0.69 (0.41-1.2) 0.78 (0.32-1.9) 
Ever had a tonsillectomy    
No REF REF REF REF 
Yes 0.84 (0.59-1.2) 0.74 (0.51-1.1) 0.80 (0.51-1.3) 1.7 (1.2-2.4) 














 (2 negative)% 
HIV-status + Current CD4 (cells/ µL)       
Negative REF REF REF REF 
Positive CD4>500  1.9 (1.4-2.6) 1.7 (1.3-2.3) 0.90 (0.75-1.1) 0.76 (0.58-0.99) 
Positive CD4 200-499  2.6 (1.9-3.6) 2.4 (1.7-3.2) 0.87 (0.72-1.1) 0.78 (0.60-1.0) 
Positive CD4<200  4.2 (2.8-6.3) 6.0 (2.7-13.3) 1.0 (0.64-1.6) 0.71 (0.50-0.99) 
p-trend <0.001 <0.001 0.94 0.42 
Age         
Younger than 45 REF REF REF REF 
45-55 0.92 (0.67-1.3) 0.89 (0.63-1.2) 0.80 (0.64-1.0) 0.88 (0.70-1.1) 
55 or older 1.2 (0.83-1.7) 0.68 (0.47-0.99) 0.73 (0.58-0.93) 0.72 (0.54-0.95) 
p-trend 0.26 0.05 0.04 0.004 
Gender         
Female (WIHS) REF REF REF REF 
Male (MACS) 0.81 (0.49-1.3) 1.5 (0.92-2.3) 0.69 (0.54-0.89) 0.84 (0.67-1.1) 
Type of Infection         
Prevalent --- --- REF REF 
Incident --- --- 2.4 (2.0-2.8) 1.6 (1.3-2.0) 
Cigarette smoking         
Never REF REF REF REF 
Former 1.6 (1.1-2.2) 0.83 (0.49-1.4) 0.73 (0.53-1.0) 0.87 (0.67-1.1) 
Current 2.8 (2.0-3.7) 0.88 (0.47-1.6) 0.67 (0.45-0.99) 0.91 (0.69-1.2) 
Ever had a 
tonsillectomy     
No REF REF REF REF 
Yes 1.0 (0.74-1.3) 0.62 (0.46-0.83) 0.86 (0.69-1.1) 0.91 (0.69-1.2) 
Unknown 2.0 (0.87-4.7) 0.92 (0.40-2.1) 0.86 (0.65-1.2) 1.5 (1.1-2.0) 
Current alcohol use     
None REF REF   
Less than 2 drinks/day 0.73 (0.56-0.94) 0.95 (0.78-1.2)   
2 or more drinks/day 0.59 (0.36-0.98) 1.0 (0.50-2.2)   
p-trend 0.004 0.94   
Recent oral sex partners       
0 REF REF     
1 0.88 (0.62-1.2) 0.79 (0.63-1.0)     
2 to 5 1.2 (0.80-1.7) 1.2 (0.91-1.7)     
6 or more 1.8 (1.0-3.0) 1.3 (0.84-2.0)     
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p-trend 0.002 0.33     
Recent oral sex on a woman    
No REF REF   
Yes 2.3 (1.4-3.8) 1.9 (1.2-2.9)   
Lifetime number of oral sex partners        
0-4 REF REF     
5 to 99 1.3 (0.95-1.7) 1.9 (1.1-3.2)     
100 or more 1.9 (1.2-2.7) 2.6 (1.6-4.3)     
p-trend 0.005 <0.001     
*Clearance models adjusted for HIV-status, current CD4 T cell count, age, type of infection, cigarette 
smoking, and history of tonsillectomy 
~Prevalence and incidence models were adjusted for HIV-status, current CD4 T cell count, age, 
cigarette smoking, study site, history of tonsillectomy, recent tooth brushing, current alcohol use, 
lifetime and recent number of oral sex partners, and recent oral sex on a woman 
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Background: Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous 
malignancy caused by HPV infection, alcohol, and tobacco use, and is elevated among HIV-
infected individuals. It is unclear if and when in the carcinogenesis process HIV-related 
immunosuppression might play a role in HNSCC development.   
Methods: Data from 17 prospective cohort studies were utilized from the North American 
AIDS Cohort Collaboration on Research and Design (NA-ACCORD). A standardized 
process of chart review and cancer registry matching was used to validate incident HNSCCs 
occurring in the HIV-infected participants between 1996-2009. HNSCCs were analyzed by 
stratifying the cancers into HPV-related and HPV-unrelated subsites, and rates were 
compared to a Surveillance Epidemiology and End Results general population estimate. Risk 
factors for incident HPV-related and HPV-unrelated HNSCC were explored using mixed 
effects Poisson regression in a full prospective analysis, and the effect of CD4 prior to 
cancer diagnosis was examined retrospectively in a nested case control analysis. 
Results:  66 HPV-related and 182 HPV-unrelated incident HNSCCs were detected among 
82,375 HIV-infected participants. The standardized incidence of both HPV-related 
(SIR=3.0, 95%CI=2.3-3.8) and HPV-unrelated (SIR=3.6, 95%CI=3.1-4.1) HNSCC was 
significantly higher among these HIV-infected individuals compared with the US general 
population. Between 1996 to 2009, HPV-related HNSCC incidence increased non-
significantly, while incidence of HPV-unrelated HNSCC decreased non-significantly. Lower 
CD4 T cell count measured up to seven years prior to cancer diagnosis was significantly 
associated with increased HPV-related and HPV-unrelated HNSCC. 
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Conclusions: The incidence of HPV-related and HPV-unrelated HNSCC are elevated in 
HIV-infected individuals. Immunosuppression may play a role in the development of both 






Human papillomavirus (HPV), tobacco, and alcohol use are three major causes of 
head and neck squamous cell carcinoma (HNSCC).1,2 In the general population of North 
America, the incidence of many types of HNSCCs, such as oral cavity cancer, have been 
decreasing over the past several decades, due to decreases in tobacco use.3,4  In contrast, 
incidence of HNSCCs related primarily to oral HPV infection, such as oropharyngeal cancer, 
have been increasing over the same time period.3-5   
Less is known about HNSCC in the HIV-infected population of North America, as 
few studies have been large enough to explore this heterogeneous malignancy. Large cohort 
and HIV/AIDS-Cancer registry match studies have suggested that HIV-infected individuals 
have a 1.5 to 4 fold higher risk for HNSCC compared with the general population.6-8 
However, many of these studies have categorized HPV-related and HPV-unrelated HNSCCs 
together in one “oral cavity and pharynx cancer” category, so it is unclear whether this 
increased HNSCC risk may be explained by higher levels of tobacco and alcohol use, higher 
exposure to HPV, faster progression of HPV-related carcinogenesis, or a combination of 
these factors.9,10    
The incidence of several cancers caused by infectious agents, such as Kaposi’s 
sarcoma, has decreased dramatically in HIV-infected individuals after the introduction of 
effective antiretroviral therapy (ART, also known as HAART or cART) around 1996. In 
contrast, there is evidence that the incidence of HPV-related cancers such as anal cancer,11,12 
and perhaps oropharyngeal cancer may be increasing in HIV-infected individuals over the 
past two decades.   
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The role of immunosuppression in the development of HNSCC is unclear as some 
preliminary studies have suggested an association with increased HNSCC risk,13-15 but 
another did not.16 Using data from the NA-ACCORD (North American AIDS Cohort 
Collaboration on Research and Design),17 a collaboration of longitudinal studies of HIV-
infected individuals, we explored the risk and trends of HPV-related and HPV-unrelated 
HNSCC, and assessed the degree to which immunosuppression plays a role in increasing 
HNSCC risk.  
Methods: 
Study Population and Design: 
The NA-ACCORD is a large collaboration of longitudinal cohort studies involving 
HIV-infected individuals in North America and is a part of the International Epidemiologic 
Databases to Evaluate AIDS (IeDEA) initiative.17 HNSCCs were identified and validated 
from three interval and fourteen clinically based cohort studies that obtain data from patient 
medical records. We included HIV-infected individuals from these 17 cohort studies who 
contributed data to the NA-ACCORD between 1996 and 2009. Individual cohorts in the 
NA-ACCORD each developed their own standardized methods of data collection. Briefly, 
each cohort submits demographic, treatment, clinical, and laboratory data to the NA-
ACCORD data management center. The data management center harmonizes the individual 
cohort datasets and implements a series of rigorous quality control procedures.  
Participant’s follow-up time for this study began at the maximum of: January 1, 1996, 
the entry into the cohort or the earliest date of cancer validation. Participants were followed 
either until the minimum of: the date of their HNSCC diagnosis, loss to follow-up, death, a 
cohort’s specific administrative censoring date or the last date of cancer validation 
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(December 31, 2009 for most cohorts). Data from the Surveillance Epidemiology and End 
Results (SEER) program on anatomical site-specific HNSCC was utilized as a general 
population comparison.18  
Data in this analysis was restricted to the ART era (1996 or later), but included both 
individuals who used and did not use ART. ART use was defined as a regimen involving at 
least three antiretrovirals, including a protease inhibitor, an entry inhibitor or an integrase 
inhibitor, or three nucleoside reverse-transcriptase inhibitors, including abacavir or tenofovir 
based on US Department of Health & Human Services/Kaiser Panel.19  Institutional review 
boards at each of the participating cohort site locations have reviewed and approved the 
human subject activities of the NA-ACCORD. 
Cancer validation and categorization: 
HNSCC cases were validated before this analysis through chart review with clinical 
confirmation from medical records/pathology reports or through cancer registry-linkage. A 
standardized abstraction survey was utilized to review each HNSCC case at 16 of the 17 
contributing cohort studies. The survey included histologic confirmation of each cancer 
along with the source of cancer confirmation and the date of diagnosis. One cohort (hereby 
called cohort A) used its own internal validation system which adheres to the North 
American Association of Central Cancer Registries quality standards. They also completed 
an additional validation process on a random subset of cases with strong sensitivity (87%) 
and positive-predictive value (96%).  
All HNSCCs were included in the analysis.20  These included all cancers classified as 
C00.0-C14.8, C30.0-C31.9, and C32.0-32.9 using the International Classification of Disease 
for Oncology version-3 (ICD-0-3) topography codes. As tumor HPV status was not 
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available in this study, all oropharyngeal cases were considered “HPV-related” in this 
analysis, as this assumption is supported by data indicating oncogenic HPV is detectable in 
approximately 50-80% of US individuals with oropharyngeal cancer.3,5  HPV-related 
HNSCCs were defined using the following ICD-0-3 topographic codes: base of the tongue 
(C01.9), lingual tonsil (C02.4), palatine tonsil (C09.0-09.9), oropharynx (C10.2-10.9), pharynx 
NOS (C14.0), and Waldyer’s ring (C14.2).3 All other HNSCCs were classified as HPV-
unrelated including: lip (C00.0-00.9), oral cavity (C02.0-02.3 and C02.5-06.9), hypopharynx 
(C12.9-13.9), nasopharynx (C11.0-11.9), salivary gland (C07.9-08.9), anterior epiglottis 
(C10.1), other overlapping sites (C14.8), nasal cavity and middle ear (C30.0-30.1), accessory 
sinuses (C31.0-31.9), and larynx (C32.0-32.9) cancers. For these analyses, cancers were 
restricted to squamous cell carcinomas, histologic ICD-O-3 codes (8050-76, 8078, 8083, 
8084, 8094) and those labeled carcinoma, NOS (8010).  
Statistical Analysis: 
The characteristics of participants who developed an incident HPV-related or HPV-
unrelated HNSCC were compared to each other and with all other NA-ACCORD 
participants who did not develop an HNSCC using χ2 tests for categorical data and 
Wilcoxon-Mann-Whitney test for medians for continuous data. Incidence rates of HPV-
related and HPV-unrelated HNSCC were calculated among HIV-infected individuals overall 
(from 1996 to 2009) and were stratified by calendar period. In order to compare subgroups 
with each other, such as the different calendar periods, we performed direct age 
standardization of these rates using the 2000 US census standard population and restricted 
to ages 20 or older in order to better match the NA-ACCORD population.18 To compare 
the rate of HNSCC in the NA-ACCORD with the US general population, standardized 
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incidence ratios (SIRs) were also calculated using indirect standardization using rates from 
Surveillance Epidemiology and End Results (SEER) from 1996-2009.18       
Mixed effects Poisson regression was utilized to model the incidence rates and 
examine risk factors for HNSCC incidence. A random intercept was used to account for 
differences in HNSCC incidence by cohort. All multivariate Poisson models included age, 
gender, smoking status and baseline CD4 T cell count.  
We also explored the effect of CD4 T cell count prior to cancer diagnosis utilizing a 
nested case control study similar to previous studies.21,22  We matched each HNSCC case to 
up to ten controls on age (+5 years), cohort, sex, and enrollment year in the study.  As 
incident density sampling was utilized, the controls had the same amount of study follow-up 
time as the cases. Reference dates were defined as the date of cancer diagnosis for HNSCC 
cases, or for controls as the date after the same length of follow-up time in the NA-
ACCORD as the matched HNSCC case. To evaluate the impact of CD4 prior to the 
reference date, we conducted an additional analysis categorizing CD4 measures into time 
periods categories prior to the reference date (less than 2 years, 2-4 years, 5-7 years, or 8-10 
years). The results were then evaluated using conditional logistic regression. For this analysis, 
if more than one CD4 cell count measurement was available for an individual case or control 
in a specific time period, then the CD4 measurement closest to the reference date was used.  
Data on participant’s cigarette smoking status was non-uniformly collected by all 
participating cohorts, and in one cohort (cohort A, the largest cohort in the NA-ACCORD), 
no smoking information was available on any participants. Overall, smoking status was 
available on 40% of the participants in our study, as 47% of our total NA-ACCORD sample 
was from cohort A, and 13% of the sample was missing smoking data and was from cohorts 
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other than cohort A. To account for this missingness in the ever smoking variable in these 
13% of individuals, stochastic multiple imputation via logistic regression was performed.23 
The binomial proportion of the time-fixed smoking variable was calculated through 
MIANALYZE from SAS and utilized other available covariates that may be associated with 
smoking status: study site, age, sex, race, HIV transmission risk, death during study, follow-
up time, CD4 and HIV RNA at entry, and ever ART use. Five random draws from this 
binomial distribution were averaged to determine the ever smoking estimate for each 
individual that was missing smoking information and to acquire the proper standard errors. 
We did not impute the smoking status for participants in cohort A as the imputation largely 
relied on having at least some participants with smoking data from the same study site.  
Results: 
Participant Characteristics: 
This study includes 82,375 HIV-infected participants from 17 cohort studies in the 
NA-ACCORD. These participants contributed 463,784 person-years between 1996 and 
2009, with a median follow-up time per participant of 4.9 (IQR=2.0-8.9) years. Only a subset 
of participants were on ART at entry into the study (20%), however most of the study 
participants had been exposed to ART by the end of the study (78%). There were 248 
incident HNSCCs ascertained throughout this study. These HNSCC cases were more likely 
to be older, male, African American, ever smokers, and have a lower CD4 T cell count 
compared with other individuals in the NA-ACCORD (Table 4.1, all p-values<0.01). 
Characteristics of individuals who developed HPV-related HNSCC were similar to those 
who developed HPV-unrelated HNSCCs, except individuals with HPV-related HNSCC 
were modestly younger. (Table 4.1, p=0.04).  
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Incidence of HPV-related and HPV-unrelated HNSCC 
 In the HIV-infected participants of NA-ACCORD, the age standardized incidence 
rate for overall HNSCC was 50.6 (95%CI=41.0-60.1) per 100,000 person-years. The 
anatomical subsites of the incident HNSCC cases in the HIV-infected individuals from the 
NA-ACCORD are described in Table 4.2. Among the 248 incident HNSCCs, there were 182 
HPV-unrelated HNSCCs and 66 HPV-related HNSCCs. The majority of HPV-unrelated 
HNSCCs were larynx and oral cavity cancers, while the most common anatomical sites for 
HPV-related HNSCCs were the lateral wall of the oropharynx and the base of the tongue 
(Table 4.2). The age-standardized incidence of HPV-unrelated HNSCC (40.0, 95%CI=31.0-
49.0 per 100,000 person-years) was significantly higher than HPV-related HNSCC (10.7, 
95%CI=7.5-13.9 per 100,000 person-years).  
Compared with the general US population from SEER, HIV-infected individuals in 
the NA-ACCORD had a three-fold higher standardized incidence of HNSCC (SIR=3.4, 
95%CI=3.0-3.8, Table 4.2). The three-fold increased incidence of cancer was consistent 
across all head and neck anatomical sites (Table 4.2), including sites related to HPV 
(SIR=3.0, 95%CI=2.3-3.8) and those not related to HPV (SIR=3.6, 95%CI=3.1-4.1).    
Incidence of HNSCC over time: 
The incidence of HNSCC did not substantially change over the course of this study, 
but there were non-significant trends which appeared to mirror the trends in the US general 
population (Figure 4.1). The age-standardized incidence of HPV-related HNSCC was close 
to twice as high in 2001-2005 (IR=12.4 per 100,000, 95%CI=7.4-17.6) compared with 1996-
2000 (6.8 per 100,000, 95%CI=1.3-12.3), although this difference was not statistically 
significant and did not continue to increase in more recent years (Figure 4.1). The age-
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standardized incidence of HPV-unrelated HNSCC remained constant between 1996 and 
2005, and then non-significantly declined in more recent years (48.6 vs. 29.3 per 100,000, 
Figure 4.1).  
Impact of risk factors on HNSCC incidence: 
Risk factors were similar for incidence of HPV-related and HPV-unrelated HNSCC. 
Older age appeared to have the strongest impact on HNSCC incidence, as older participants 
had a significantly higher incidence of HPV-related HNSCC, as well as HPV-unrelated 
HNSCC, after adjustment for other risk factors(both p<0.001, Table 4.3). In addition, ever 
smokers and those with a lower baseline CD4 T cell count both had an non-significantly 
elevated incidence of HPV-related and HPV-unrelated HNSCC after adjustment (Table 4.3). 
The incidence of both HPV-related and HPV-unrelated HNSCC were similar among 
men who have sex with men, other males, and females. In addition, HPV-related and HPV-
unrelated HNSCC incidence was similar by race, baseline HIV RNA viral load, and baseline 
CD8 T cell count.  Those not on ART at baseline had a similar incidence of HPV-related 
HNSCC, but a lower incidence of HPV-unrelated HNSCC compared to those on ART at 
baseline.  
In a sensitivity analysis, we considered the effect of risk factors on HNSCC incidence 
by cohort and observed modest differences between the cohort A and the other cohorts in 
the NA-ACCORD (Table 4.4). We found that, qualitatively, reduced baseline CD4 was more 
strongly associated with HPV-related HNSCCs than HPV-unrelated HNSCCs in cohort A, 
while in the other cohorts, reduced CD4 was more strongly associated to HPV-unrelated 
HNSCCs. However, these interactions did not reach statistical significance (p-
interactions>0.20, Table 4.4). To determine if this potential difference by cohort was due to 
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the lack of smoking data in the cohort A, we ran another sensitivity analysis that excluded 
the participants in cohort A. We found that adjusting for ever smoking status did not 
strongly impact the point estimates between risk factors and HPV-related or HPV-unrelated 
HNSCC in the non-cohort A studies (Table 4.5). In addition, we found that the baseline 
CD4 T cell count in ever and never smokers was similar (p=0.90). 
Impact of CD4 cell count on HNSCC incidence: 
After finding that reduced baseline CD4 T cell count may be associated with 
increased HNSCC incidence, we further explored the effect of reduced CD4 by conducting a 
nested case control analysis. This nested case-control analysis considered CD4 measures in 
cases and controls prior to a reference date, which was defined as the date of cancer 
diagnosis for cases or the date after the same length of follow-up in the NA-ACCORD as 
the matched HNSCC case for controls. When measured up to seven years prior to the 
reference date, reduced CD4 T cell count measured was associated with HPV-related and 
HPV-unrelated HNSCC (Figure 4.2, Table 4.6). CD4 cell count measured within two years 
prior the reference date was associated with both HPV-related (CD4<200: aOR=2.3, 
95%CI=1.1-4.8) and HPV-unrelated HNSCC (CD4<200: aOR=3.3, 95%CI=2.0-5.6). 
Similar associations were seen when CD4 was measured up to seven years prior to the 
reference date for both HPV-related and HPV-unrelated HNSCC (Table 4.6), although there 
was a suggestion that the association may have strengthened further from the reference date 
for HPV-related HNSCC (5-7 years, CD4<200: aOR=5.1, 95%CI=1.5-17.3). 
Discussion: 
In this large prospective study, we determined that the incidence of HPV-related and 
HPV-unrelated HNSCC were both threefold higher in HIV-infected individuals than the US 
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general population. This study also supports a modest role for immunosuppression prior to 
cancer diagnosis, which suggests when paired with other studies,7,24 that immunosuppression 
from HIV may have some impact during the oral carcinogenesis process.  
The three fold higher incidence of HNSCC in this HIV-infected population 
compared with the general population is consistent with previous registry based studies 
which have suggested that the incidence of HNSCC is between 1.5 and 4 fold higher in 
HIV-infected individuals.6,7  In addition, the incidence of HPV-related HNSCC increased 
while the incidence of HPV-unrelated HNSCC decreased among these HIV-infected 
individuals between 1996 and 2009, which mirrors what has been observed in the general 
HIV-uninfected population.3,5 However, the calendar trends in this study were modest and 
did not reach statistical significance. This may, in part, be explained by the imprecise 
groupings of cancers in our study by tumor subsite, since HPV status was unavailable; as 
some cases in the HPV-related HNSCC group were likely HPV-negative this 
misclassification may have attenuated actual trends.  
It has been speculated that the higher incidence of HNSCC in HIV-infected 
individuals might be due to multiple different factors including: their increased use of 
tobacco or alcohol, their higher number sexual partners, and/or from HIV-related 
immunosuppression.7,25 However, the effect of immunosuppression on HNSCC incidence 
has not been extensively explored previously. Most previous studies that include HNSCCs in 
HIV-infected individuals have been limited to exploring the role of CD4 T cell count at one 
time point, and have not explored the effect immunosuppression trends over time.14,15 Our 
study supports the conclusion that immunosuppression may have a modest role in the 
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development of HNSCC,13-15 and suggests this may be true for both HPV-related and HPV-
unrelated HNSCC.  
Our finding that HPV-related HNSCC is associated with immunosuppression 
measured up to seven years prior to cancer diagnosis, is consistent with other studies 
suggestion immunosuppression is associated with higher incidence of HNSCC13-15 and with 
increased risk of acquisition of oral HPV infection (Beachler unpublished). It has been 
previously speculated that immunosuppression may have its strongest impact earlier in the 
HPV-related carcinogenesis process26 however; initial finds exploring the longitudinal effect 
of CD4 on other HPV-associated cancers have been mixed. One recent study suggested that 
immunosuppression may have its largest effect 6-7 prior to anal cancer diagnosis,22,26 while 
another study suggested a stronger effect close to cervical cancer diagnosis.21 The results of 
this NA-ACCORD study found that lower CD4 measured further from HPV-related 
HNSCC diagnosis (5-7 years vs. 0-2 years) may be more strongly associated with HPV-
related HNSCC; however the difference between these CD4 measures was not significant.  
The finding that immunosuppression was also similarly associated with HPV-
unrelated HNSCC in this study suggests that reduced immune surveillance for malignant 
cells could have a role in HNSCC development.27,28 There have been several recent studies 
that have suggested immunosuppression closer to cancer diagnosis may impact infection and 
non-infection related non-AIDS defining malignances.9,13,29,30  For example, a study from 
Kaiser Permante13 suggested that reduced recent CD4 was associated with a higher risk of 
both infection related and non-infection related cancers, except prostate cancer. 
Alternatively, it is also conceivable that undiagnosed HNSCC may be playing a role in 
reducing a participant’s immune status. A recent European study found a higher risk of 
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cancer diagnosis within six months of a detectable decline in CD4 count, suggesting that the 
decline in CD4 may be a consequence of the cancer rather than a causal agent in the 
malignancy’s development.31  
While we note a modest association between immunosuppression and HPV-related 
HNSCC risk, the three fold higher SIR for HPV-related HNSCC (comparing HIV-infected 
individuals with the general population) is considerably lower than the SIRs for other HPV-
associated cancers including cervical, anal, and vulvar cancer (SIRs>5).6,14,32  It is possible 
that the SIR of HPV-related HNSCC may be lower due to the demographics and sexual 
orientation of the North American HIV-infected population.6,7 Specifically, the incidence of 
HNSCC may be modest in North American HIV-infected individuals as ~75% are either 
heterosexual women or MSM33 and there is evidence that performing oral sex on a man may 
be less likely to transmit oral HPV infection than performing it on a woman.7,34 However in 
this study heterosexual men had a similar incidence of HPV-related HNSCC compared to 
MSM and women, although we were unable to adjust for important risk factors such as 
number of lifetime oral sex partners.  
 There are several strengths to this study. The study used prospective data from a 
large collaboration of HIV-studies that have been suggested to be representative of the HIV-
infected population in clinical care in North America.17 In addition, this study included a 
rigorous standardized validation procedure to confirm malignancies, included approximately 
15 years of data, and is one of the first studies to explore HPV-related and HPV-unrelated 
HNSCC incidence among HIV-infected individuals. However, we should note that we 
lacked detailed information on other co-factors such as sexual behavior, alcohol use, and 
detailed tobacco use (such as current tobacco use and cumulative tobacco use) and thus the 
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risk factor’s associations with HNSCC are still prone to residual confounding. In addition, 
there was outcome misclassification as all oropharyngeal cancers were classed HPV-related 
in this study. While a recent case series suggests that HPV is detected in most oropharyngeal 
cancers in HIV-infected individuals,35 there were still likely HPV-negative oropharyngeal 
cancers that were classified as HPV-related HNSCCs in this study. This may impact both the 
HPV-related SIR and the association of risk factors, although results were relatively similar 
between the HPV-related and HPV-unrelated HNSCCs in this study.  
 This study demonstrates that North American HIV-infected individuals have an 
elevated risk of both HPV-related and HPV-unrelated HNSCC. However, these SIRs are 
relatively modest compared to other virally induced carcinomas, suggesting that the North 
American HIV-infected population as a whole may not be strong candidates for more 
aggressive HNSCC screening modalities. While there has not been a strong decline in 
HNSCC incidence in the antiretroviral therapy era, these results and others suggest that 
immunosuppression may play a role during the HNSCC carcinogenesis process, which 
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 Table 4.1: Characteristics of the participants in NA-ACCORD compared with those with 
HPV-related and HPV-unrelated Head and Neck Squamous Cell Carcinomas (HNSCCs) 





HNSCC (n=66)  
HPV-unrelated 
HNSCC (n=182) 
Median Age at Baseline (IQR) 42.8 (36-49.7) 48.5 (43.4-52.3) 49.0 (44.4-55.3) 
Gender/Sexual Orientation    
Female 11,308 (14%) 5 (7.6%) 14 (7.6%) 
Male (heterosexual and MSM) 71,308 (86%) 61 (92.4%) 168 (92.3%) 
   MSM only* 20,960 (50%)* 8 (47%) 15 (40%) 
Race    
Black (non-Hispanic) 31,411 (38%) 35 (53%) 86 (47%) 
White 36,588 (47%) 24 (36%) 91 (50%) 
Other 13,897 (17%) 7 (10%) 5 (2.8%) 
Median Year of Entry (IQR) 2000 (1997-2004) 1999 (1997-2000) 1998 (1997-1998) 
Median Years of Follow-up 
(IQR) 
4.9 (2.0-8.9) 4.7 (3.7-6.0) 4.5 (3.6-5.1) 
Median CD4 T Cell Count at 
Baseline (IQR) 
293 (127-487) 248 (189-327) 240 (205-322) 
Current ART use at baseline 15,990 (20%) 12 (19%) 44 (24%) 
Ever ART during Study 64,072 (78%) 54 (82%) 137 (75%) 




9479 (400-63608) 15,100 (971-78032) 
<500 copies/mL 14,388 (18%) 15 (23%) 17 (16%) 
>500 copies/mL 64,587 (81%) 51 (77%) 92 (84%) 
Smoking*    
Ever 31,857 (76%) 21 (84%) 44 (92%) 
Never 10,016 (24%) 4 (16%) 4 (8.3%) 
Stage of Cancer    
T1-T2 n/a 38 (58%) 118 (64%) 
T3-T4 n/a 19 (29%) 32 (18%) 
Unknown n/a 9 (14%) 32 (18%) 

















Table 4.2: Head and Neck Squamous Cell Carcinomas in NA-ACCORD compared to the 







Total Head Neck Squamous Cell Carcinomas (HNSCCs) 248 3.4 (3.0-3.8) 
HPV-related – Oropharynx 66 3.0 (2.3-3.8) 
  Oropharynx - Lateral Wall/Tonsil/Posterior Wall/Unspecified 43 3.4 (2.4-4.5) 
  Base of Tongue 20 2.3 (1.4-3.6) 
  Pharynx, NOS 4 4.3 (1.2-11.0) 
HPV-unrelated 182 3.6 (3.1-4.1) 
   Larynx/Hypopharynx/Supraglottis 95 4.2 (3.4-5.2) 
   Oral Cavity 56 3.0 (2.3-3.9) 
   Lip 10 2.9 (1.4-5.3) 
   Paranasal sinus/Nasal cavity/Middle ear 9 5.3 (2.4-10.1) 
   Nasopharynx 8 3.3 (1.0-4.8) 












 Age Standardized Incidence Rates per 100,000 person-years among the HIV-
positive participants in the NA-ACCORD 
Calendar Period HPV-unrelated HPV-related 
1996-2000 41.9 (27.8-56.0) 6.8 (1.3-12.3) 
2001-2005 48.6 (31.1-66.1) 12.4 (7.1-17.6) 
2006-2009 29.3 (19.1-39.5) 11.4 (5.6-17.1) 




Table 4.3: Unadjusted and adjusted incidence rate ratios for risk factors for HPV-related and 
HPV-unrelated Head and Neck Squamous Cell Carcinoma (HNSCC) 
Variable HPV-related HNSCC HPV-unrelated HNSCC 
  IRR aIRR^ IRR aIRR^ 
Age         
<40 REF REF REF REF 
40-50 3.4 (1.6-7.1) 3.3 (1.5-7.6) 4.9 (2.8-8.2) 4.7 (2.6-8.5) 
50+ 4.2 (1.9-9.2) 4.9 (2.0-11.9) 8.5 (4.9-14.5) 7.3 (3.9-13.7) 
Gender         
Female REF REF REF REF 
Male 1.6 (0.55-4.3) 1.1 (0.40-3.0) 1.7 (0.81-3.7) 1.1 (0.50-2.2) 
   MSM^ 1.0 (0.32-3.1) --- 0.88 (0.35-2.2) --- 
   Other Men^ 1.1 (0.29-4.1) --- 1.0 (0.41-2.6) --- 
Race         
Black REF --- REF --- 
White 0.69 (0.41-1.2) --- 1.3 (0.78-1.4) --- 
Other 0.63 (0.24-1.7) --- 0.23 (0.09-0.60) --- 
Smoking status         
Never REF REF REF REF 
Ever 2.5 (0.57-10.8) 2.5 (0.57-11) 3.0 (1.1-8.4) 2.7 (0.96-7.6) 
ART use at baseline         
Yes REF --- REF --- 
No 1.0 (0.53-1.8) --- 0.68 (0.48-0.96) --- 
Baseline CD4     
>500 cells/uL REF REF REF REF 
200-500 cells/uL 2.0 (0.86-4.7) 1.9 (0.82-4.4) 1.7 (0.97-2.8) 1.6 (0.92-2.7) 
<200 cells/uL 1.8 (0.74-4.5) 1.6 (0.82-4.4) 1.9 (1.1-3.3) 1.7 (0.98-2.3) 
Baseline HIV viral 
load 
    
<500 copies/mL REF --- REF --- 
500-10000 copies/mL 0.49 (0.22-1.1) --- 0.74 (0.41-1.3) --- 
>10000 copies/mL 0.49 (0.23-1.0) --- 0.94 (0.55-1.6) --- 
Baseline CD8     
Highest (Quartile 1) REF --- REF --- 
Quartile 2 2.0 (0.37-11.0) --- 0.42 (0.13-1.4) --- 
Quartile 3 2.1 (0.38-11.7) --- 0.74 (0.27-2.0) --- 
Quartile 4 1.1 (0.15-7.5) --- 0.74 (0.28-2.0) --- 





Table 4.4 – The effect of risk factors on HPV-related and HPV-unrelated HNSCC stratified 
by whether a participant is a part of the Cohort A 
Covariate 
IRR~ 
HPV-related HNSCC HPV-unrelated HNSCC 
All Others 
Cohorts 




Age         
<40 years old REF REF REF REF 
40-50 years old 2.2 (0.81-6.1) 5.2 (1.6-17.1) 7.7 (3.1-19.0) 3.2 (1.7-6.3) 
50 years old or older 3.1 (0.91-10.6) 5.1 (1.5-17.5) 14.0 (5.2-37.3) 5.7 (3.0-10.8) 
p-interaction* 0.29 0.35 
Sex     
Female REF REF REF REF 
Male 1.0 (0.36-1.8) ---^ 0.84 (0.37-1.9) ---^ 
Baseline CD4       
>500 cells/uL REF REF REF REF 
200-500 cells/uL 1.8 (0.58-5.8) 2.1 (0.60-7.6) 4.6 (1.6-13.3) 0.90 (0.48-1.7) 
<200 cells/uL 0.91 (0.23-3.6) 2.7 (0.76-9.6) 2.7 (0.85-8.8) 1.5 (0.82-2.8) 
p-interaction* 0.21 0.53 
*p-interaction test is between cohort status and CD4 (350 cells/ul) 
~Not adjusted for other risk factors 





Table 4.5: The effect of risk factors on HPV-related and HPV-unrelated HNSCC among 
cohorts with available smoking data* 
Immunosuppression 
Covariate HPV-related HNSCC HPV-unrelated  HNSCC 
  IRR aIRR^ IRR aIRR^ 
Age         
<40 REF REF REF REF 
40-50 2.2 (0.81-6.1) 2.2 (0.80-6.2) 7.7 (3.1-19.0) 7.4 (3.0-18.4) 
50+ 3.1 (0.91-10.6) 3.2 (0.93-11.2) 14.0 (5.2-37.3) 13.8 (5.2-36.9) 
Sex     
Female REF REF REF REF 
Male 1.0 (0.36-1.8) 0.90 (0.32-2.5) 0.84 (0.37-1.9) 0.74 (0.32-1.7) 
Baseline CD4          
>500 cells/uL REF REF REF REF 
200-500 cells/uL 1.8 (0.58-5.8) 1.7 (0.54-5.3) 4.6 (1.6-13.3) 4.2 (1.5-12.2) 
<200 cells/uL 0.91 (0.23-3.6) 0.74 (0.18-3.0) 2.7 (0.85-8.8) 2.2 (0.69-7.2) 
^ Poisson regression modeling that adjusted for age, gender, ever smoking status and cohort 








Figure 4.2: Median CD4 T cell counts measured before the reference date among HPV-related 
HNSCC cases, HPV-unrelated HNSCC cases, and matched controls in the NA-ACCORD 
 
 
*Error Bars represent the 95% confidence intervals for each time point. The reference date was 
defined for HPV-unrelated and HPV-related HNSCC cases as the date of HNSCC diagnosis and for 





Table 4.6: Impact of different measures of CD4 T cell count on HPV-related and HPV-
unrelated HNSCC in the HIV-infected individuals in the NA-ACCORD 





  aOR^ aOR^ 
CD4 0-1 years before Cancer Diagnosis/Reference Date* 
  
>500 cells/uL REF REF 
200-500 cells/uL 1.8 (0.90-3.6) 1.7 (1.0-2.8) 
<200 cells/uL 2.3 (1.1-4.8) 3.3 (2.0-5.6) 
CD4 2-4 years before Cancer Diagnosis/Reference Date*  
 
>500 cells/uL REF REF 
200-500 cells/uL 1.2 (0.61-2.5) 1.6 (1.0-2.6) 
<200 cells/uL 1.6 (0.73-3.6) 4.2 (2.6-7.2) 
CD4, 5-7 years before Cancer Diagnosis/Reference Date*   
>500 cells/uL REF REF 
200-500 cells/uL 3.1 (1.0-9.5) 2.2 (1.1-4.1) 
<200 cells/uL 5.1 (1.5-17.3) 4.2 (2.1-8.4) 
CD4, 8-10 years before Cancer Diagnosis/Reference Date*   
>500 cells/uL REF REF 
200-500 cells/uL 1.7 (0.41-6.7) 1.5 (0.50-4.2) 
<200 cells/uL 0.35 (0.03-6.7) 5.1 (1.8-15.0) 
^10 controls were matched to each HNSCC cases and were matched on age (+5 years), cohort, sex, 
and enrollment year in the study. Using conditional logistic regression models, the association with 
each CD4 measure was considered separately and was adjusted for smoking status and current ART 
status.  
*Controls were matched to cases utilizing incident density sampling, thus the reference dates for 









Chapter 5: Conclusions and Future Directions 
Summary of Results: 
 The focus of this dissertation was to investigate oral HPV infection and Head and 
Neck Squamous Cell Carcinoma (HNSCC), an understudied but emerging issue particularly 
in higher income countries.1 In this dissertation, we concentrated on a group expected to 
have a particularly high burden of this disease, HIV-infected individuals.  
The goals of this dissertation were 1) to compare the natural histories of oral HPV 
and anal HPV infection among HIV-infected individuals (chapter two), 2) to evaluate the 
effect of HIV-related immunosuppression along with other risk factors on oral HPV 
incidence and clearance in HIV-infected and HIV-uninfected individuals (chapter three), and 
3) to examine the incidence, calendar trends and risk factors for HNSCC in HIV-infected 
individuals (chapter four).  
In the second chapter of this dissertation, we utilized the Human Oral 
Papillomavirus Etiology (HOPE) study to explore the natural history of oral and anal HPV 
infections in 404 HIV-infected women, heterosexual men, and Men who have Sex with Men 
(MSM) in a HIV-related care clinic in Baltimore, MD.  This study suggested that over half of 
the incident anal and oral HPV infections clear within two years and that there is a mix of 
persistent and intermittent infections in this immunosuppressed HIV-infected population.  
We hypothesized that the incidence of anal HPV would be considerably higher than 
oral HPV, and that the persistence of both infections would be similar. We did indeed find 
that the incidence of anal HPV was five-fold higher than oral HPV infection, but we also 
noted the persistence of anal HPV was modestly higher than oral HPV even after 
adjustment for various risk factors. This suggests that HPV may be less transmissible to the 
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oral cavity and pharynx potentially due to a lower propensity for epithelial microtrama and 
possibly easier to clear due to unspecified immunologic features or other microbiota found 
in the oral region.2 In addition, the higher incidence and persistence of anal compared to oral 
HPV infection likely partially explains why there is a much higher burden of HPV-associated 
anal cancer than HPV-associated HNSCC in HIV-infected individuals.3,4  
Our second hypothesis involving the HOPE study was that HIV-infected MSM 
would have the highest hazard of incident anal HPV infection, while heterosexual men 
would have the highest hazard of incident oral HPV infection after adjusting for other 
factors such as the number of sexual partners. While both anal and oral HPV infections were 
detected in all three subgroups, anal HPV incidence was higher in MSM and women 
compared to heterosexual men, while oral HPV incidence was higher in heterosexual men 
than the women and MSM.  This supports other evidence implying that anal HPV is often 
acquired through receptive anal intercourse, and suggests that oral HPV may be more likely 
to be acquired from performing oral sex on a woman (cunnilingus) than performing oral sex 
on a man (fellatio). However, it is also possible that heterosexual men may have a higher 
incidence of oral HPV due to their lower level of antibodies to the L1 capsid of HPV that 
may protect against subsequent oral HPV infection.5-7 
 In chapter three, we utilized two long term HIV-studies, the Multicenter AIDS 
Cohort Study (MACS) and the Women’s Interagency HIV Study (WIHS), to evaluate the 
effect of HIV-infection, immunosuppression, and other risk factors on the incidence and 
clearance of oral HPV infection. Our nested study, the Persistent Oral human 
Papillomavirus Study (POPS), was able to evaluate these factors given its larger sample size 
of 1,230 HIV-infected and HIV-uninfected participants from the MACS and WIHS and 
strong retention rate.  
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Similar to the HOPE study, we found that over a quarter of HIV-infected and HIV-
uninfected individuals in the POPS had a newly detected oral HPV infection within two 
years of follow-up, but the majority of these oral HPV infections cleared fairly rapidly. 
Counter to our original hypothesis, we did not observe an association between 
immunosuppression and reduced oral HPV clearance in the POPS. Instead, we observed a 
strong association between immunosuppression and increased oral HPV incidence. This 
suggests that the increased prevalence of oral HPV infection in HIV-infected individuals 
reported in previous cross-sectional studies 8-10 is likely explained by an increase in oral HPV 
incidence and not from a difference in oral HPV clearance.  
The incident oral HPV infections detected in the POPS and HOPE studies were 
likely a combination of both newly acquired infections and re-activated infections. Oral HPV 
incidence was associated with a higher number of recent oral sex and rimming partners in 
HIV-uninfected individuals in the POPS, particularly among the small subset of individuals 
reporting that they recently performed oral sex on a woman. This suggests that some of 
these incident oral HPV infections were likely newly acquired. In addition, oral HPV 
incidence was associated with an increased lifetime number of oral sex partners, and we also 
observed a relatively high incidence of oral HPV infection in individuals reporting sexual 
abstinence throughout the POPS. This suggests that some newly detected infections are 
likely not newly acquired, but rather they are infections that were previously acquired and are 
being re-activated similar to what has been in observed in studies exploring cervical HPV.11,12  
We also explored other risk factors for oral HPV clearance and incidence within the 
POPS. Clearance of oral HPV was lower in older compared to younger individuals, in 
current compared to never cigarette smokers, and in MACS men compared to WIHS 
143 
 
women. This supports other studies suggesting that tobacco may reduce local immune 
function,13,14 and that women may have a stronger immune response to infectious diseases 
like HPV potentially due to endocrine differences.15  In addition to HIV-related 
immunosuppression and increased sexual behavior, oral HPV incidence was also associated 
with never having a tonsillectomy, and a younger age.  
In Chapter four of this dissertation, we followed North American HIV-infected 
individuals over time and examined the incidence and risk factors for HNSCC, a malignancy 
often caused by oral HPV infection. For this aim we included 82,375 HIV-infected 
individuals from the North American AIDS Cohort Collaboration on Research and Design 
(NA-ACCORD), which included 17 clinical and interval cohort studies who contributed data 
from the antiretroviral era between 1996 and 2009.   
This study found that the age-standardized incidence of HPV-related and HPV-
unrelated HNSCC were both approximately three times higher in the HIV-infected NA-
ACCORD population compared to the general population (SIR=3.4, 95%CI=3.0-3.8). In 
addition, we found that age-standardized incidence of HNSCC in HIV-infected individuals 
was relatively constant during the ART era (1996-2009). However, there was a non-
significant increase in HPV-related HNSCC when comparing the more recent era (2001-
2010) to the early ART era (1996-2000) suggesting that HPV-related HNSCC may be 
modestly increasing similar to the general population.1,16   
The incidence of HPV-related and HPV-unrelated HNSCC was higher in those with 
a low CD4 T cell count after adjustment for other risk factors. While results from the POPS 
and others have suggested that immunosuppression may have the strongest impact on the 
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earlier stages of the HPV-related carcinogenesis process,17,18 we observed that low CD4 
closer to cancer diagnosis may also have an impact on HNSCC incidence.  
Public Health Implications 
 There are several implications to this research. This dissertation finds that both the 
prevalence of oral HPV infection and HPV-related HNSCC are modestly elevated in HIV-
infected individuals, but is still a relatively less common malignancy in HIV-infected 
individuals particularly compared to other HPV-related malignancies such as anal cancer. We 
found that HPV-related HNSCC may be modestly increasing in HIV-infected individuals 
over time, while the incidence of HPV-unrelated HNSCC may be declining. 
 This dissertation research suggests that oral HPV is commonly detected in HIV-
infected individuals, but most of these infections are cleared or controlled quickly even in 
the more immunosuppressed HIV-infected individuals. We also found that oral HPV is less 
commonly detected than anal HPV in HIV-infected individuals, and oral HPV is potentially 
cleared or controlled ever quicker than anal HPV. Therefore there are likely specific factors 
in the oral cavity and pharynx that can impact HPV that need more exploration. In addition, 
this suggests that a one-time measurement of an oral HPV infection, even oral HPV16, has a 
low specificity for subsequent HNSCC and is not useful in predication for this malignancy. 
This argues against utilization of oral HPV DNA alone as an oral cancer screening test. 
The high number of intermittent infections and evidence of re-activation of latent 
infection seen in our studies suggest that immunosuppressed individuals in particular, may 
have difficultly continually controlling their oral HPV infections or may be more likely to re-
acquire previously cleared oral HPV infections. However, it does appear that most 
individuals are able avoid continual persistence of oral HPV infection, regardless of their 
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CD4 T cell count. This suggests that immune re-constitution through utilization of 
antiretroviral therapy (ART) may be primarily beneficial in reducing the re-activation or the 
acquisition of oral HPV infection. However, considering the association between HPV-
related HNSCC and reduced CD4 near cancer diagnosis, it is possible that immune 
competency could be beneficial at multiple stages in the natural history of this disease. This 
suggests that there may be an eventual reduction in the age-standardized incidence of 
HNSCC in HIV-infected individuals in developed countries. As HIV-infected individuals in 
developed countries are now initiating ART more quickly after their HIV diagnoses,19 they 
will likely reduce their cumulative amount of time being immunosuppressed, which could 
reduce their subsequent risk for HNSCC. 
 Another important implication of this research is that heterosexual men may be at 
higher risk of oral HPV acquisition and subsequent HNSCC compared to MSM and 
heterosexual women. This may partially explain why the incidence HPV-related HNSCC 
isn’t as common as some other HPV-associated cancers in the HIV-infected population of 
the United States given that heterosexual men and WSW likely only represent around 25% of 
this population.19 However, the proportion of heterosexual men infected with HIV is 
considerably higher in lower income countries.  Thus, it is possible that the incidence of 
HPV-associated HNSCC may be higher in HIV-infected individuals in low income 
countries. Exploration is warranted. 
 This research is also one of the first to report that both rimming and oral sex likely 
have roles in transmitting oral HPV infection. Thus, it implies that reducing certain sexual 
behaviors could reduce the likelihood of acquiring this oncogenic infection, although the co-
linearity between these behaviors and the possibility of re-activation of oral HPV infection 
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makes it difficult to determine the exact risk of these behaviors. Finally, this dissertation’s 
finding that oral HPV is still acquired in this middle aged population suggests that it is 
possible that the prophylactic HPV vaccines may have some potential benefit in populations 
outside the individuals currently recommended for vaccination (HIV-infected and HIV-
uninfected individuals aged 11-26).20,21  
Directions for Future research: 
Based on the results of this dissertation, there are several different areas for future 
research. Future studies involving oral HPV infection should work to better understand: 1) 
how oral HPV is acquired, 2) the role of factors specific to the oral region such as oral 
antibodies, and 3) the role of gender on infection and cancer incidence. In addition, studies 
including HNSCCs should further explore immunosuppression’s role in HPV’s 
carcinogenesis process, and examine the proportion of HNSCCs that are positive for HPV 
particularly in HIV-infected individuals. Finally, evaluation of potential preventative 
measures such as HPV vaccination and potential screening markers in higher risk 
populations are warranted.    
While this dissertation suggests oral sex and rimming are transmitters of oral HPV 
infection, further work is needed to better elucidate how oral HPV is acquired considering 
the considerable number of infections not explained by oral sex or rimming behavior. 
Prospective studies including younger partners are warranted to explore the role of deep 
(French) kissing, autoinoculation, and other potential ways to transmit this virus. 
We also found that the natural history of oral HPV infection may differ from anal 
HPV.  I am involved with others in conducting further comparisons between oral HPV and 
anogenital HPV infection in studies such as the MACS and WIHS. There is still a need to 
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better understand factors specific to the oral region that could impact the natural history of 
oral HPV and HPV-associated HNSCC. Comparing HPV at different anatomical sites and 
exploring factors that could modify the risk of disease such as a history of tonsillectomy, oral 
specific antibodies (IgG and IgA), and oral microbiota are worthy of further exploration.  
Another area of further interest is exploring the differences in the natural history of 
oral HPV and HNSCC by gender. Recent studies have suggested that prevalence of oral 
HPV infection is higher in males,22 and that HPV-associated HNSCC is around three times 
as prevalent in males compared to females.1,16  However, the reasons for male predominance 
of HPV-associated HNSCC are undetermined. As previously mentioned, this dissertation 
provides some modest evidence that this difference may be at least partially due to a 
difference in transmission risk between sexual acts. It still undetermined whether cunnilingus 
may be more likely to transmit oral HPV than fellatio due to a higher viral load in the vagina, 
or whether the difference may be due to differing prevalence’s of natural protective 
antibodies to the L1 capsid protein.23 It is possible that the male predominance of HPV-
associated HNSCC may also be due to a difference in oral HPV persistence, as women may 
clear their infections more quickly due to gender related endocrine differences. 15 These 
hypotheses need further investigation in the more general HIV-uninfected population. 
Considering that females have a more robust immune response to many infectious diseases 
and that males more commonly develop cancer at shared anatomic sites,24 this research 
could be extended to other cancers and considered in future preventative strategies.  
While this dissertation found that immunosuppression may primarily act on the 
earliest stages of carcinogenesis (oral HPV incidence), we also found that 
immunosuppression may play a role near HNSCC diagnosis. Thus there is still a need to 
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better understand the timing of immunosuppression and how it can impact cancer etiology 
and survival particularly in populations such as the HIV-infected and organ transplant 
recipients. A better understanding of the role of inflammation and/or immunosurveillance 
on HPV-related HNSCC and other malignancies is necessary. This is especially important 
for HIV-infected individuals as it could help inform when antiretroviral therapy could be 
best initiated in terms of cancer prevention.  
Oral HPV infection has been detected in approximately 70% of oropharyngeal 
cancers in the general population of the United States,1 however it is undetermined what 
proportion of oropharyngeal cancers and other HNSCCs in HIV-infected individuals are 
caused by oral HPV. Other oncogenic HPV types besides HPV16 are more commonly 
detected in HIV-infected individuals,8,25 thus other types should be tested for and considered 
in HNSCC tumors. This would be particularly enlightening given that currently the only 
oncogenic HPV types that the prophylactic HPV vaccines protect against are HPV16 and 
HPV18. 
Further evaluation of the HPV vaccine efficacy in HIV-infected individuals is 
warranted. Initial studies suggest that the vaccine is safe and immunogenic in this 
population,26  and several on-going trials are further exploring this question.27 Recent 
observational studies have suggested that cervical pre-cancerous lesion recurrence is lower 
among individuals vaccinated after their first excision/conisation.28 Thus, while the 
prophylactic HPV vaccines have shown to protect against newly acquired infection, it is 
unclear, but possible, that vaccination may also protect against re-acquisition or re-activation 
of oral HPV infection. The high incidence of oral HPV infection in this dissertation coupled 
with the high level of cervical and anal disease burden in HIV-infected individuals may 
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support vaccinating these individuals older than 26. However, further study from 
randomized control trials is necessary. 
 Finally, future studies should consider the efficacy of cancer screening markers for 
HPV-associated HNSCC in the HIV-infected population. A recent nested case-control study 
suggested that antibodies to HPV16 E6 are very strongly associated with HNSCC detected 
ten or more years later (OR=274, 95%CI=110-681).29  Thus, we are now conducting a study 
exploring whether antibodies to this oncoprotein are detectable in the cancer free POPS 
population who have persistently detected oral HPV16 DNA. A beneficial screening test for 
HPV-associated HNSCC is difficult to develop considering HNSCC is a relatively 
uncommon malignancy, even among higher risk groups. Thus screening markers such as 
HPV16 E6 would require an extremely high specificity, and should not be recommended 
until further validation from randomized control trials with mortality as the end-point. 
Conclusions: 
This dissertation examined the natural history of oral HPV infection and HNSCC 
among HIV-infected individuals. We present two of the first studies exploring the natural 
history of oral HPV infection, and find that oral HPV is commonly detected in this HIV-
infected population, but the majority of these infections clear quickly.  We also contributed 
to the body of research that suggests that HPV-related HNSCC is modestly elevated in HIV-
infected individuals, but it still not a common malignancy in this population and not rapidly 
increasing in the ART era. We find that immunosuppression may have the strongest effect 
on oral HPV incidence as it may lead to increased risk of both newly acquired and re-
activation of latent oral HPV infection. Additionally, we suggest that HIV-infected 
heterosexual men may be at higher risk of newly acquired infection and subsequent 
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malignancy. Future research is necessary to better understand the impact of risk factors 
including HIV and immunosuppression on oral HPV and HNSCC.  Additionally, research 
on preventative methods such as HPV vaccination and exploration of screening markers in 
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Lack of impact of HPV16 seropositivity on the 
subsequent risk of oral HPV16 infection 
 
Abstract: 
Introduction: Previous studies have suggested that Immunoglobulin G (IgG) antibodies to 
virus like particles (VLP) to the HPV L1 capsid protein acquired through a natural infection 
may protect against the subsequent incidence of cervical HPV infection. However, it is 
underdetermined how HPV VLP seropositivity may impact the risk of oral HPV infection. 
Methods:  Serum samples from 476 HIV-infected and 297 at risk HIV-uninfected 
participants were tested for antibodies at study baseline to virus-like particles to the L1 
capsid protein of HPV16 using an enzyme linked immunosorbent assay (ELISA). Oral rinse 
samples were collected at semi-annually follow-up visits for up to three years. DNA was 
isolated from the oral rinse and tested using PGMY 09/11 primers. Adjusted Poisson and 
Wei-Lin-Weissfeld regression modeling were utilized. 
Results: 23% of HIV-infected and 20% of HIV-uninfected individuals were HPV16 
seropositive. HPV16 seropositivity was not associated with baseline oral HPV16 DNA 
detection (aPR=0.50, 95%CI=0.18-1.4), but was associated with baseline anal HPV16 DNA 
detection among the MACS participants (aPR=2.3, 95%CI=1.5-3.7). The risk of incident 
oral HPV infection during follow-up was similar comparing individuals who were HPV16 




Conclusions:  Oral HPV may be less likely to induce a natural antibody response compared 
to anal HPV. Natural HPV16 seropositivity does not appear to reduce the subsequent risk of 





 While HPV infection is commonly detected in the genital tract, these infections often 
clear or are controlled within twelve months.1,2 These transient anogenital infections have 
been shown to often induce a natural immune response to virus-like particles (VLPs) from 
the L1 capsid protein of HPV. These natural developing serum immunoglobulin G (IgG) 
antibodies have been suggested to be a surrogate measure for cumulative lifetime exposure 
to HPV, 3-6 although they have limited sensitivity as there are some individuals who are 
exposed to HPV DNA that do not seroconvert. Further, some initial studies suggest people 
with natural HPV antibodies may reduce the risk of subsequently acquiring a new cervical 
HPV infection of that type 7,8 although other studies have not seen an association.9,10  
Serum IgG antibodies generated in response to a genital HPV infection could 
potentially protect not only against subsequent anogenital infection but also against 
acquisition of subsequent oral HPV infection. However, as there have only been a few 
studies exploring the natural history of oral HPV, whether natural serum VLP antibodies 
may provide protection against subsequent risk of incident oral HPV infections has not been 
explored. Oral HPV16 infections are of particular interest as they are the mostly commonly 
detected type in the oral region,11,12 and are known to cause over 85% of HPV positive Head 
and Neck Squamous cell carcinomas (HNSCC).13  
We utilized a longitudinal cohort study of HIV-infected and at risk HIV-uninfected 
individuals expected to have a high HPV seroprevalence to VLPs to explore the relationship 





 For this study, 773 individuals were selected from the Persistent Oral human 
Papillomavirus Study (POPS). The POPS includes HIV-infected and at risk HIV-infected 
participants from the Multicenter AIDS Cohort Study (MACS) and the Women Interagency 
HIV Study (WIHS), and is further described elsewhere.11,14,15 All participants that enrolled 
into the POPS between 2009 and 2010 and had four or more follow-up visits at the time of 
this sample selection for antibody testing were included. The executive committees of the 
MACS and WIHS and the Institutional Review Boards from each site approved the study 
protocol. All POPS participants provided written informed consent. 
 Banked serum was collected from each individual’s baseline POPS visit and tested 
for HPV16 VLP antibodies. This data was linked to the oral HPV results and risk factor 
information at the baseline POPS visit and every six month follow-up visit as previously 
described in chapter three of this dissertation. In addition, anal swab samples collected from 
MACS participants at the around the same time as the POPS baseline visit were evaluated.  
Laboratory testing: 
Antibody testing was performed on banked serum samples at the POPS baseline by 
using a virus-like particle (VLP)-ELISA with HPV 16 capsids produced in insect cells from 
recombinant baculoviruses following previously published methods with some modifications 
(VLP production6; ELISA16).  For quality assurance, known positive controls were run on 
each 96 well ELISA plate throughout the testing period. For any run where the controls gave 
optical density (OD) values outside of an acceptable limit, the plate was re-run. 
Oral HPV16 DNA was collected through a 30 second rinse and gargle with saline or 
ScopeTM mouthwash.17 In the MACS, anal swab specimens were also collected and tested for 
anal HPV DNA. The DNA from the anal swabs was collected using a saline-moistened 
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Dacron swab that was inserted six cm into the anal canal and removed in a circular motion 
against the anal wall. The swab was placed in 1 mL of Sample Transport Medium (Digene 
Diagnostics, Silver Spring, MD).18  DNA was isolated from these samples using a magnetic 
bead-based automated platform (QIAsymphony SP, Qiagen),19 and then tested for the 37 
different HPV types utilizing the Roche linear array with PGMY09/11 primers PCR primer 
pools and reverse line blot hybridization similar to chapter 3 of this dissertation and other 
previous studies which further describes these assays.11,17,19   
Statistical methods 
To compare baseline HPV16 seroprevalence between various risk factors, we utilized 
Chi-square tests for categorical variables and Mann-Whitney tests for medians for 
continuous variables.  Individuals were considered seropositive when the optical density of 
the test was above a cutpoint of 0.2 (determined based on previous studies).6 Optical density 
was also considered as a continuous variable in these analyses.  
As previously mentioned in chapters 2 and 3, type specific oral HPV infection was 
classified as prevalent if detected at baseline and as incident if first detected after a negative 
type-specific test at baseline. Unadjusted Poisson regression with robust variance was used 
for analyzing risk factors for baseline HPV16 seroprevalence.  Unadjusted and adjusted Wei-
Lin-Weissfeld (WLW) models were utilized to explore whether HPV16 seroprevalence may 
impact subsequent oral HPV incidence.  These marginal models involve Cox proportional 
hazard assumptions with an exchangeable correlation structure and robust variance to adjust 
for multiple infections with a single individual.20  All statistical tests were two sided and 
considered significant using an alpha=0.05 level. All analyses were performed by STATA 





Among the 773 participants who contributed four or more study visits to the POPS, 
there were 174 (22%) who were seroprevalent for HPV16 VLP at the POPS baseline visit. 
HPV16 L1 seropositivity was similar by HIV-status (HIV+ vs. HIV-: 23% vs. 20%, p=0.25), 
gender (male vs. female: 23% vs. 21%, p=0.36), and age (Table A.1).  In unadjusted analysis, 
higher seroprevalence of HPV16 VLP was observed in those with a current CD4 T cell 
count<200 cells/uL, in never smokers, and in those with two or more recent oral sex 
partners (Table A.1, all p<0.05). After adjustment with other risk factors, never smoking 
cigarettes, increased number of recent oral sex partners, and reduced current  CD4 T cell 
count all remained associated with increased HPV16 VLP seroprevalence (Table A.1, all 
p<0.05). When optical density values were considered continuously, HPV16 antibody titer 
levels were similar between HIV-infected and HIV-uninfected individuals (Figure A.1).  
  We compared the baseline HPV16 seropositivity to the prevalence of anal and oral 
HPV DNA at baseline (Table A.2).  We observed that HPV16 seropositivity was associated 
both any anal HPV prevalence at baseline (PR=1.2, 95%CI=1.1-1.4) and anal HPV16 DNA 
prevalence at baseline (PR=2.3, 95%CI=1.5-3.7). In addition, when HPV16 antibody titer 
was considered as a continuous variable, higher antibody titer remained strongly associated 
with baseline anal HPV16 DNA prevalence (p-trend=0.007, Table A.2).  In contrast, HPV16 
seropositivity was not associated with either oral HPV prevalence at baseline (PR= 1.1, 
95%CI=0.88-1.4) or oral HPV16 DNA prevalence at baseline (PR=0.50, 95%CI=0.18-1.4, 
Table A.2). Only 13% of individuals who were oral HPV16 positive at baseline were HPV16 
seroprevelant, while a larger proportion (43%) of those were anal HPV16 positive at baseline 
were HPV16 seroprevelant at baseline (p=0.004).  
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Baseline seropositivity to HPV16 VLP did not reduce subsequent risk of any oral 
HPV infection (aHR=1.0, 95%CI=0.76-1.3) or oral HPV16 infection (aHR=1.1, 
95%CI=0.41-3.0) in this study (Table A.3). Similarly there was no observed association when 
considering the antibody titer’s optical density continuous or by quartile (Table A.3).  
Seropositivity did not reduce subsequent oral HPV16 risk in either HIV-infected 
(aHR=0.92, 95%CI=0.23-3.6) or HIV-uninfected (aHR=2.2, 95%CI=0.56-8.3) individuals. 
When restricting to individuals who reported that they performed oral sex during the study, 
seropositivity to HPV16 VLP at baseline remained unassociated with subsequent risk of oral 
HPV16 infection (HR=3.1, 95%CI=0.74-13.1, Table A.3).  
Discussion: 
 This study suggests that HPV16 seropositivity does not have a protective effect on 
subsequent acquisition of oral HPV infection. In addition, we find that natural HPV16 
antibody responses may be elicited more frequently by anogenital infections than oral 
infections, as HPV16 seroreactivity was associated with anal but not oral HPV16 DNA 
prevalence detected at the same baseline visit.  
 This study is one of the first to examine whether natural antibody response may be 
protective against subsequent oral HPV infection. Similar to two other cervical HPV 
studies,9,10 we do not observe any protective effect of higher HPV16 antibody titer on 
subsequent risk of oral HPV16 infection. However, this contrasts with several other 
previous cervical HPV studies, which suggested that high HPV16 antibody titer from natural 
infection can reduce subsequence cervical HPV infection risk, 7,8 including a large recent 
study that suggested that the risk of subsequent infection was halved in those with high 
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HPV16 antibody tier.7 It is unclear whether antibody response may have a differential impact 
on anogenital HPV infection compared to oral HPV infection risk. 
As suggested in chapter 3 in this dissertation, the incident oral HPV infections 
detected in the POPS were often intermittent and may represent reactivated infection rather 
than newly acquired infection particularly in HIV-infected individuals. Thus, the high 
number of re-activated infection may have impacted these results; however that was still no 
evidence of protection when restricting to individuals recently performing oral sex or among 
HIV-uninfected individuals alone. 
 Previous studies report that HPV16 seroprevalence is considerably higher in both 
women and MSM compared to heterosexual males, potentially due to their exposure to HPV 
at mucosal sites (anus/cervix) compared to heterosexual male’s non-mucosal site (genitals) 
.21,22 Thus, one proposed explanation of the male predominance of oral HPV infection and 
HPV-positive oropharyngeal cancer is that the higher HPV seroreactivity in women (and 
MSM) may protect them from subsequent oral HPV infection.23 However, results from this 
study do not support this hypothesis. This suggests the higher incidence of oral HPV 
infection among heterosexual males may be due other factors such a potential higher risk of 
oral HPV transmission through cunnilingus compared to fellatio.24  
The antibody titer response to natural HPV infection is considerably lower than 
those conferred from HPV vaccination through the Gardisil or Cervarix vaccines.7,25,26 While 
formal clinical trials have not been performed, a recent study does suggest that the HPV 
vaccine may provide protection against subsequent oral HPV infection, in addition to the 
protection it confers against anogenital HPV infection.27  
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Our study’s lack of association between baseline oral HPV DNA and HPV 
seropositivity is consistent with a cross-sectional study that also did not observe an 
association between oral HPV 16/18/33 DNA prevalence and HPV16/18/33 seropositivity 
in women. 22 However, we did observe an association between baseline anal HPV DNA and 
HPV seropositivity, suggesting that natural HPV16 antibody responses may be more likely 
conferred by anogenital infections. It is possible, that oral HPV may be less likely to induce 
an immune response because the viral loads of these infections are often lower than 
anogenital infections (Beachler unpublished).  
HPV seropositivity has been associated to anogenital HPV prevalence in some,28,29 
but not all studies6 as seropositivity is more likely to be associated with past rather than 
current HPV16 DNA positivity.30  Thus further explanation needs to be explored on 
whether past oral HPV DNA may confer a subsequent antibody response similar to 
anogenital HPV infection.   
There are several limitations and strengths to this study. The ELISA assay is limited 
as there are no standard reference serum samples and the assay has been suggested to only 
detect an antibody response only 50-60% infections.22,29  In addition, this study population 
has reduced generalizability to the general population. However, this is one of the first 
studies to explore the effect of HPV16 antibody response on subsequent incidence of oral 
HPV16 and utilizes a well-established cohort study, and robust laboratory and statistical 
methods. 19,20 
This study suggests that natural HPV16 seroprevalence may not protect against the 
subsequent acquisition of oral HPV16 infection in a higher risk cohort. Further studies are 
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necessary to verify this result and explore whether serum antibody response may differ by 
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Table A.1: Characteristics of the 773 POPS serology participants by HPV16 VLP serostatus in 
unadjusted and adjusted modeling 
 
Characteristics of POPS participants 
HPV16 
Seropositive 
HPV16 VLP Serology 
  n=174 Unadjusted (PR) Adjusted (PR) 
Age*       
Younger than 45 27% REF REF 
45-55 20% 0.70 (0.47-1.1) 0.68 (0.43-1.1) 
55 or older 20% 0.69 (0.45-1.1) 0.64 (0.38-1.1) 
p-trend   0.32 0.34 
Gender      
Female (WIHS) 21% REF REF 
Male (MACS) 23% 1.2 (0.84-1.6) 1.2 (0.57-2.5) 
Cigarette Smoker*      
Never 28% REF REF 
Former 19% 0.58 (0.37-0.90) 0.60 (0.38-0.96) 
Current 20% 0.62 (0.41-0.91) 0.65 (0.41-1.0) 
Recent oral sex partners      
0 18% REF REF 
1 24% 1.4 (0.94-2.2) 1.6 (1.0-2.6) 
2 to 5 30% 1.9 (1.2-3.0) 2.2 (1.3-3.8) 
6 or more 32% 2.1 (1.1-3.9) 2.3 (1.0-5.1) 
p-trend   0.10 0.26 
Lifetime number of oral sex partners      
0-4 20% REF REF 
5 to 99 22% 1.1 (0.74-1.7) 1.0 (0.61-1.6) 
100 or more 26% 1.4 (0.90-2.2) 0.92 (0.48-1.8) 
p-trend   0.03 0.25 
HIV-infection      
No 20% REF REF 
Yes 23% 1.2 (0.86-1.8) 1.4 (0.96-2.1) 
HIV-status + CD4 T cell count*      
Negative 20% REF REF 
Positive CD4>500 cells/µL 23% 1.2 (0.83-1.9) 1.4 (0.89-2.1) 
Positive CD4 200-499 cells/µL 21% 1.1 (0.69-1.7) 1.3 (0.79-2.1) 
Positive CD4<200 cells/µL 33% 2.0 (0.98-4.2) 3.0 (1.4-6.6) 





Figure A.1:  The distribution of the optical density of HPV16 Antibody Titer among the 773 HIV-
negative and HIV-positive participants from the POPS.  
 
*The difference in OD values between HIV-negative and HIV-positive participants were not 






























Table A.2: HPV16 serology relationship to oral and anal HPV16 and any HPV DNA at baseline of 
POPS 










HPV16 VLP Seropositive         
No REF REF REF REF 
Yes 0.50 (0.18-1.4) 1.1 (0.88-1.4) 2.3 (1.5-3.7) 1.2 (1.1-1.4) 
HPV16 VLP antibody titer         
Q1 (lowest) REF REF REF REF 
Q2 2.2 (0.78-6.3) 1.0 (0.78-1.4) 1.6 (0.42-6.2) 1.1 (1.0-1.1) 
Q3 2.2 (0.78-6.2) 1.3 (0.98-1.7) 4.2 (1.3-13.6) 1.3 (1.2-1.3) 
Q4 (highest) 1.0 (0.30-3.5) 1.2 (0.94-1.6) 5.9 (1.9-18.8) 1.4 (1.4-1.5) 
continuous p-trend 0.45 0.10 0.007 <0.001 
 
Table A.3: Baseline Seroprevalence and subsequent risk of oral HPV infection in the POPS 
  Oral HPV16 incidence Oral HPV incidence 




HR Adjusted HR^ 
HPV 16 VLP 
seropositive     
No REF REF REF REF 
Yes 1.4 (0.60-3.4) 1.1 (0.41-3.0) 1.2 (0.87-1.5) 1.0 (0.76-1.3) 
HPV16 VLP antibody titer     
Q1 (lowest) REF REF REF REF 
Q2 1.0 (0.26-4.2) 1.1 (0.23-5.2) 1.2 (0.80-1.8) 1.0 (0.70-1.5) 
Q3 2.3 (0.67-7.6) 2.2 (0.60-7.9) 1.4 (0.97-2.1) 1.1 (0.77-1.7) 
Q4 (highest) 1.8 (0.52-5.9) 1.4 (0.37-5.5) 1.4 (0.99-2.0) 1.1 (0.79-1.6) 
continuous p-trend 0.39 0.78 0.21 0.45 
HPV16 seropositivity restricted to those performing oral 
sex      
No REF REF REF REF 
Yes 2.5 (0.82-7.4) 3.1 (0.74-13.1) 1.5 (1.0-2.6) 1.4 (0.99-2.1) 
 
^adjusted for HIV-status, current CD4 T cell count, age, cigarette smoking, study site, history of 
tonsillectomy, recent tooth brushing, current alcohol use, lifetime and recent number of oral sex 
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